

## PRODUCT MONOGRAPH

**PrProlia<sup>®</sup>**  
(denosumab)

60 mg/mL solution for injection  
Prefilled Syringe

Professed Standard

RANK Ligand Inhibitor  
(Bone Metabolism Regulator)

Physicians should become fully familiarized with the efficacy/safety profile of PROLIA and the full content of the Product Monograph prior to prescribing the drug.

Amgen Canada Inc.  
6775 Financial Drive, Suite 100  
Mississauga, Ontario  
L5N 0A4

Date of Approval:  
August 24, 2017

Submission Control No: 198125

© 2010-2017 Amgen Canada Inc., All rights reserved

**Table of Contents**

**PART I: HEALTH PROFESSIONAL INFORMATION..... 3**

SUMMARY PRODUCT INFORMATION ..... 3

DESCRIPTION..... 3

INDICATIONS AND CLINICAL USE..... 3

CONTRAINDICATIONS ..... 4

WARNINGS AND PRECAUTIONS..... 5

ADVERSE REACTIONS..... 11

DRUG INTERACTIONS ..... 39

DOSAGE AND ADMINISTRATION ..... 40

OVERDOSAGE ..... 41

ACTION AND CLINICAL PHARMACOLOGY ..... 41

STORAGE AND STABILITY..... 44

DOSAGE FORMS, COMPOSITION AND PACKAGING ..... 44

**PART II: SCIENTIFIC INFORMATION ..... 45**

PHARMACEUTICAL INFORMATION..... 45

CLINICAL TRIALS..... 45

DETAILED PHARMACOLOGY ..... 53

TOXICOLOGY ..... 54

REFERENCES ..... 61

**PART III: CONSUMER INFORMATION..... 63**

**PrProlia®**  
(denosumab)

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form / Strength</b>	<b>Clinically Relevant Nonmedicinal Ingredients</b>
Subcutaneous	Solution for injection / 60 mg denosumab in 1 mL solution in a single use prefilled syringe	Single use prefilled syringe: sorbitol, acetate, polysorbate 20, water for injection (USP) and sodium hydroxide.  <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i>

**DESCRIPTION**

PROLIA (denosumab) is a human IgG2 monoclonal antibody with affinity and specificity for human RANK ligand (RANKL) that inhibits RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of RANKL-RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption. Denosumab has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.

PROLIA is supplied as a single use, sterile, preservative-free, clear, colourless to slightly yellow solution formulated at pH 5.2. PROLIA is supplied in a 60 mg/mL prefilled syringe (PFS) presentation with a 1.0 mL volume and intended for delivery by subcutaneous injection.

**INDICATIONS AND CLINICAL USE**

**Postmenopausal Osteoporosis**

PROLIA (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, PROLIA reduces the incidence of vertebral, nonvertebral and hip fractures (see **CLINICAL TRIALS**).

**Treatment to Increase Bone Mass in Men with Osteoporosis at High Risk for Fracture**

PROLIA is indicated as a treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or

patients who have failed or are intolerant to other available osteoporosis therapy (see **CLINICAL TRIALS**).

### **Treatment to Increase Bone Mass in Men with Nonmetastatic Prostate Cancer receiving Androgen Deprivation Therapy (ADT), who are at high risk for fracture**

PROLIA is indicated as a treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT), who are at high risk for fracture (see **CLINICAL TRIALS**).

### **Treatment to Increase Bone Mass in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Nonmetastatic Breast Cancer**

PROLIA is indicated as a treatment to increase bone mass in women with nonmetastatic breast cancer receiving adjuvant aromatase inhibitor (AI) therapy, who have low bone mass and are at high risk for fracture (see **CLINICAL TRIALS**).

### **Geriatrics (≥ 65 years of age)**

The majority of patients treated with PROLIA in the postmenopausal osteoporosis (PMO) clinical trial were ≥ 65 years old (see **WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics**).

Of the patients in the osteoporosis study in men, 133 patients (55%) were ≥ 65 years old, while 39 patients (16%) were ≥ 75 years old.

In the clinical trial of men with bone loss associated with ADT for nonmetastatic prostate cancer, 1364 patients (93%) were ≥ 65 years old.

In a clinical trial of women with bone loss associated with adjuvant AI therapy for breast cancer, 76 patients (30%) were ≥ 65 years old.

### **Pediatrics**

The safety and efficacy of PROLIA have not been studied in pediatric populations. PROLIA is not indicated for use in pediatric patients (see **WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics**).

## **CONTRAINDICATIONS**

- Patients who are hypersensitive to the drug or any component of the product. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section of the product monograph. Anaphylactic reactions have been reported (see **WARNINGS AND PRECAUTIONS, Hypersensitivity** and **ADVERSE REACTIONS, Postmarket Adverse Drug Reactions**).
- Hypocalcemia (see **WARNINGS AND PRECAUTIONS, Endocrine and Metabolism, Hypocalcemia**)
- Female patients who are pregnant. PROLIA may cause fetal harm when administered to a pregnant woman. In utero denosumab exposure in cynomolgus monkeys resulted in increased fetal loss, stillbirths, and postnatal mortality, along with evidence of absent lymph nodes, abnormal bone growth and decreased neonatal growth. If this drug is used during

pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus (see **WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women**).

## **WARNINGS AND PRECAUTIONS**

### **General**

Adequate intake of calcium and vitamin D is important in all patients.

PROLIA contains the same active ingredient as found in XGEVA® (denosumab). Patients being treated with PROLIA should not be treated concomitantly with XGEVA.

### **Endocrine and Metabolism**

#### **Hypocalcemia**

Hypocalcemia must be corrected by adequate intake of calcium and vitamin D prior to initiating therapy with PROLIA. Other disorders affecting mineral metabolism (such as vitamin D deficiency) should be treated. Clinical monitoring of calcium levels is recommended before each dose and, in patients predisposed to hypocalcemia (eg, history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment [creatinine clearance < 30 mL/min] or receiving dialysis), within two weeks after the initial dose (see **Monitoring and Laboratory Tests**). Calcium levels should be measured if any patient presents with suspected symptoms of hypocalcemia during treatment.

Patients should be advised to report to their physicians any symptoms of hypocalcemia, such as paresthesias or muscle spasms, twitching and muscle cramps (see **ADVERSE REACTIONS, Hypocalcemia**).

In the postmarket setting, severe symptomatic hypocalcemia has been reported (see **ADVERSE REACTIONS, Postmarket Adverse Drug Reactions, Severe Hypocalcemia**), with most cases occurring in the first weeks of initiating therapy but it can occur later. Examples of the clinical manifestations of severe symptomatic hypocalcemia have included QT interval prolongation, tetany, convulsions and altered mental status.

#### **Hypersensitivity**

Clinically significant hypersensitivity reactions including anaphylaxis have been reported with PROLIA. Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.

If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate treatment immediately and discontinue further use of PROLIA (see **CONTRAINDICATIONS and ADVERSE REACTIONS**).

#### **Infections**

In a 3-year clinical trial in women with postmenopausal osteoporosis, serious infections leading to hospitalization were reported more frequently in the PROLIA group (4.1%) than in the placebo group (3.4%). Skin infections leading to hospitalization were reported more frequently in the PROLIA (0.4%) versus the placebo (< 0.1%) groups. These cases were predominantly

cellulitis. As well, infections of the abdomen, urinary tract, and ear, were more frequent in patients treated with PROLIA. Endocarditis was also reported more frequently in PROLIA-treated patients (< 0.1% PROLIA group; 0% placebo group). The incidence of opportunistic infections was balanced between PROLIA and placebo groups and the overall incidence of skin infections was similar between the PROLIA (1.5%) and placebo (1.2%) groups. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of severe infection, including cellulitis and erysipelas (see **ADVERSE REACTIONS, Infections**).

Patients on concomitant immunosuppressant agents or with impaired immune systems may be at increased risk for serious infections. Consider the benefit-risk profile in such patients before treating with PROLIA. In patients who develop serious infections while on PROLIA, prescribers should assess the need for continued PROLIA therapy.

### **Dermatologic**

In a large, 3-year clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the PROLIA (10.8%) group compared to the placebo (8.2%) group. Most of these events were not specific to the injection site. Consider discontinuing PROLIA if severe symptoms develop (see **ADVERSE REACTIONS, Dermatologic**).

### **Osteonecrosis of the Jaw (ONJ)**

Osteonecrosis of the jaw (ONJ) has been reported in patients treated with denosumab or bisphosphonates, another class of anti-resorptive agents. Most cases have been in cancer patients; however, some have occurred in patients with osteoporosis. The risk of ONJ may increase with duration of exposure to PROLIA. ONJ has been reported in clinical studies in patients receiving denosumab at a dose of 60 mg every 6 months for osteoporosis. There have been reports of ONJ in clinical studies in patients with advanced cancer treated with denosumab at the studied dose of 120 mg administered every 4 weeks.

Known risk factors for ONJ include previous treatment with bisphosphonates, older age, smoking, a diagnosis of cancer, concomitant therapies (eg, chemotherapy, antiangiogenic biologics, corticosteroids, radiotherapy to head and neck), poor oral hygiene, invasive dental procedures (eg, dental extractions, dental implants, oral surgery), and co-morbid disorders (eg, periodontal and/or other pre-existing dental disease, ill-fitting dentures, anemia, coagulopathy, infection).

It is important to evaluate patients for risk factors for ONJ before starting treatment. A dental examination with appropriate preventative dentistry is recommended prior to treatment with PROLIA in patients with risk factors for ONJ.

Good oral hygiene practices should be maintained during treatment with PROLIA. Patients should receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling during treatment with PROLIA.

Avoid invasive dental procedures during treatment with PROLIA. For patients in whom invasive dental procedures cannot be avoided, the clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.

Patients who are suspected of having ONJ or patients who develop ONJ during treatment with PROLIA should receive care by a dentist or an oral surgeon. In patients who develop ONJ during treatment with PROLIA, a temporary interruption of treatment should be considered based on individual risk/benefit assessment until the condition resolves (see **ADVERSE REACTIONS, Osteonecrosis of the Jaw (ONJ)**).

### **Atypical Femoral Fractures**

Atypical femoral fractures have been reported in patients receiving PROLIA. Atypical femoral fractures may occur with little or no trauma in the subtrochanteric and diaphyseal regions of the femur and may be bilateral. Specific radiographic findings characterize these events. Atypical femoral fractures have also been reported in patients with certain comorbid conditions (eg, vitamin D deficiency, rheumatoid arthritis, hypophosphatasia) and with use of certain pharmaceutical agents (eg, bisphosphonates, glucocorticoids, proton pump inhibitors). These events have also occurred without antiresorptive therapy. During PROLIA treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Patients presenting with such symptoms should be evaluated for an incomplete femoral fracture, and the contralateral femur should also be examined.

### **Multiple Vertebral Fractures (MVF) Following Discontinuation of PROLIA Treatment**

Multiple vertebral fractures (MVF) may occur following discontinuation of treatment with PROLIA, particularly in patients with a history of vertebral fracture.

Advise patients not to interrupt PROLIA therapy without their physician's advice. Evaluate the individual benefit/risk before discontinuing treatment with PROLIA. If PROLIA treatment is discontinued, consider transitioning to an alternative antiresorptive therapy.

### **Suppression of Bone Turnover**

In clinical trials in women with postmenopausal osteoporosis, treatment with PROLIA resulted in significant suppression of bone remodeling as evidenced by markers of bone turnover and bone histomorphometry. The significance of these findings and the effect of long-term treatment with PROLIA are unknown. Monitor patients for osteonecrosis of the jaw, atypical fractures, and delayed fracture healing (see **ADVERSE REACTIONS, Fracture Healing, Osteonecrosis of the Jaw (ONJ); ACTION AND CLINICAL PHARMACOLOGY, Pharmacodynamics; CLINICAL TRIALS, Bone Histology and Histomorphometry**).

### **Malignancies**

See **Clinical Trial Adverse Drug Reactions**.

## **Special Populations**

### **Pregnant Women**

There have been no studies in pregnant women.

PROLIA is indicated only for women who are postmenopausal (see also **Pediatrics** below) and is not recommended for women who could become pregnant.

PROLIA may cause fetal harm when administered to a pregnant woman based on findings in animal studies (see **CONTRAINDICATIONS** and **PART II, TOXICOLOGY, Animal Toxicology**).

Developmental toxicity studies have been performed in cynomolgus monkeys at AUC exposures of up to 100-fold higher than the human exposure. No evidence of impaired fertility was observed.

In a study of cynomolgus monkeys dosed with denosumab during the period equivalent to the first trimester at AUC exposures up to 99-fold higher than the human dose (60 mg every 6 months), there was no evidence of maternal or fetal harm. In this study, fetal lymph nodes were not examined.

In another study, in utero denosumab exposure in cynomolgus monkeys at 50 mg/kg body weight every 4 weeks, from gestation day 20 through to parturition resulted in increased fetal loss, stillbirths and post-natal mortality. Findings in the infants included skeletal abnormalities resulting from impaired bone resorption during rapid growth, reduced bone strength and treatment-related bone fractures; reduced hematopoiesis; tooth malalignment and dental dysplasia (in the absence of adverse effects on tooth eruption); absence of peripheral lymph nodes; and decreased neonatal growth. There was no evidence of maternal toxicity. Maternal mammary gland development was normal.

Studies in mice suggest absence of RANKL during pregnancy may interfere with maturation of the mammary gland leading to impaired lactation postpartum (see **PART II, TOXICOLOGY, Animal Toxicology**).

### **Nursing Women**

PROLIA is not recommended for use in nursing women (see also **Pediatrics** below). It is not known whether PROLIA is excreted into human milk. Because PROLIA has the potential to cause adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug.

### **Males**

PROLIA may cause fetal harm.

The extent to which PROLIA is present in seminal fluid is unknown. There is a potential for fetal exposure to PROLIA when a man treated with PROLIA has unprotected sexual intercourse with a pregnant partner. The risk of fetal harm is unknown. Advise men being treated with PROLIA of this potential risk to a partner who could become pregnant.



## **Pediatrics**

The safety and effectiveness of PROLIA in pediatric patients have not been studied.

PROLIA is not recommended in pediatric patients. Adolescent primates (cynomolgus monkeys) dosed with denosumab at 27 and 150 times (10 and 50 mg/kg dose) the clinical exposure based on AUC had abnormal growth plates. In neonatal rats, inhibition of RANKL (target of denosumab therapy) with a construct of osteoprotegerin bound to Fc (OPG-Fc) at high doses was associated with inhibition of bone growth and tooth eruption. Therefore, treatment with PROLIA may inhibit bone growth in children with open growth plates and may inhibit eruption of dentition. In neonatal cynomolgus monkeys exposed in utero to denosumab at 50 mg/kg, there was increased post-natal mortality; skeletal abnormalities resulting from impaired bone resorption during rapid growth, reduced bone strength and treatment-related bone fractures; reduced hematopoiesis; tooth malalignment and dental dysplasia (in the absence of adverse effects on tooth eruption); absence of peripheral lymph nodes; and decreased neonatal growth. Following a recovery period from birth out to 6 months of age, findings still observed were mildly reduced bone length (femoral, vertebral, jaw), reduced cortical thickness with associated reduced strength; extramedullary hematopoiesis; dental dysplasia; and the absence or decreased size of some lymph nodes. One infant had minimal to moderate mineralization in multiple tissues (see **PART II, TOXICOLOGY, Animal Toxicology**).

## **Geriatrics (≥ 65 years of age)**

### Females

In the PMO clinical trial, 94.7% of the patients who received PROLIA were ≥ 65 years old and 31.6% were ≥ 75 years old. No overall differences in safety or efficacy were observed between patients ≥ 65 years old and patients ≥ 75 years old. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

In a clinical trial of women with bone loss associated with adjuvant AI therapy for breast cancer, 30% of the patients who received PROLIA were ≥ 65 years old.

### Males

In the male osteoporosis trial, no overall differences in efficacy were observed in patients ≥ 65 years of age (N = 133) who received PROLIA, compared with younger patients. However, greater sensitivity of some older individuals cannot be ruled out.

There were 133 patients (55%) ≥ 65 years of age, of whom 39 patients (16%) were ≥ 75 years. The incidence of adverse events (AEs) in patients ≥ 65 and ≥ 75 years of age were 107 events in 50 patients (73.5%) and 30 events in 14 patients (70.0%) in the PROLIA group vs. 124 events in 43 patients (67.2%) and 45 events in 12 patients (63.2%) in the placebo group, respectively; the incidence of serious adverse events (SAEs) were 14 events in 10 patients (14.7%) and 5 events in 4 patients (20.0%) in the PROLIA group vs. 8 events in 6 patients (9.4%) and 1 event in 1 patient (5.3%) in the placebo group, respectively. The incidence of AEs in patients < 65 years of age were 61 events in 36 patients (69.2%) in the PROLIA group vs. 100 events in 41 patients (73.2%) in the placebo group; the incidence of SAEs in patients < 65 years of age were 2 events in 1 patient (1.9%) in the PROLIA group vs. 5 events in 4 patients (7.1%) in the placebo group.

In the clinical trial of men with bone loss associated with ADT for nonmetastatic prostate cancer, 93% of the patients who received PROLIA were  $\geq 65$  years old. No overall differences in safety or efficacy were observed between these patients and younger patients.

For men with sexual partners who could become pregnant, see also **Special Populations, Pregnant Women**.

### **Renal Impairment**

In a study of 55 patients with varying degrees of renal function, including patients on dialysis, the degree of renal impairment had no effect on the pharmacokinetics of denosumab; thus, dose adjustment for renal impairment is not necessary.

In clinical studies, patients with severe renal impairment (creatinine clearance  $< 30$  mL/min) or receiving dialysis were at greater risk of developing hypocalcemia. Adequate intake of calcium and vitamin D is important in patients with severe renal impairment or receiving dialysis (see **WARNINGS AND PRECAUTIONS, Hypocalcemia**).

### **Hepatic Impairment**

The safety and efficacy of PROLIA have not been studied in patients with hepatic impairment.

### **Monitoring and Laboratory Tests**

Clinical monitoring of calcium is recommended before each dose. In patients with a history of hypocalcemia, or signs and symptoms of hypocalcemia or predisposed to hypocalcemia (eg, history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment [creatinine clearance  $< 30$  mL/min] or receiving dialysis), clinical monitoring of calcium levels is recommended within the first 2 weeks of the initial dose. Calcium levels should be measured if any patient presents with suspected symptoms of hypocalcemia during treatment. (See **WARNINGS AND PRECAUTIONS, Hypocalcemia**)

### **Information to be Provided to the Patient**

Patients must be adequately supplemented with calcium and vitamin D. All patients should be instructed on the importance of calcium and vitamin D supplementation in maintaining serum calcium levels. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of hypocalcemia (eg, paresthesias or muscle spasms) (see **PART III: CONSUMER INFORMATION**).

Patients should be advised to seek prompt medical attention if they develop signs or symptoms of cellulitis.

Patients should be aware of the most commonly associated side effects of PROLIA therapy.

If a dose of PROLIA is missed, the injection should be administered as soon as convenient. Thereafter, injections should be scheduled every 6 months from the date of the last injection.

## **Latex Sensitivity Allergies**

The patient or caregiver should be informed that the needle cap on the single use prefilled syringe contains dry natural rubber (a derivative of latex), which should not be handled by persons with a known sensitivity to latex.

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

A total of 8091 women (4050 PROLIA vs. 4041 placebo) were enrolled in placebo-controlled studies of women with postmenopausal osteoporosis or low bone mass (Study 1 and Study 2), and a total of 242 men (121 PROLIA vs. 121 placebo) were enrolled in a placebo-controlled study of men with osteoporosis (Study 5). A total of 1468 men (734 PROLIA vs. 734 placebo) were enrolled in a placebo-controlled study of bone loss in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT) (Study 6). A total of 252 women (127 PROLIA vs. 125 placebo) were enrolled in a placebo-controlled study of bone loss in women with breast cancer receiving adjuvant aromatase inhibitor (AI) therapy (Study 7).

### **Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

### **Treatment of Postmenopausal Osteoporosis**

The safety of PROLIA in the treatment of postmenopausal osteoporosis was assessed in a large, 3-year, randomized, double-blind, placebo-controlled, multinational study of 7808 postmenopausal women aged 60 to 91 years with osteoporosis (Study 1). A total of 3876 women received placebo and 3886 women received PROLIA administered once every 6 months as a single 60 mg subcutaneous (SC) dose. All women received calcium (at least 1000 mg) and vitamin D (at least 400 IU) supplementation per day. The incidence of adverse events was 93% in both treatment groups (n = 3605 in the PROLIA group and 3607 in the placebo group). The 3 most common adverse events overall were back pain (1347 [34.7%] PROLIA, 1340 [34.6%] placebo), arthralgia (784 [20.2%] PROLIA, 782 [20.2%] placebo), and hypertension (614 [15.8%] PROLIA, 636 [16.4%] placebo). The most common adverse events (> 5% and more common than placebo) were back pain (1347 [34.7%] PROLIA, 1340 [34.6%] placebo), pain in extremity (453 [11.7%] PROLIA, 430 [11.1%] placebo), hypercholesterolemia (280 [7.2%] PROLIA, 236 [6.1%] placebo), musculoskeletal pain (297 [7.6%] PROLIA, 291 [7.5%] placebo) and cystitis (228 [5.9%] PROLIA, 225 [5.8%] placebo). The incidence of serious adverse events was 25.8% (n = 1004) in the PROLIA group and 25.1% (n = 972) in the placebo group. The 3 most common serious adverse events were osteoarthritis (63 [1.6%] PROLIA, 79 [2.0%] placebo), atrial fibrillation (36 [0.9%] PROLIA, 33 [0.9%] placebo), and pneumonia (34 [0.9%] PROLIA, 36 [0.9%] placebo). Deaths occurred in 70 subjects (1.8%) in the denosumab group and 90 subjects (2.3%) in the placebo group. Adverse events leading to treatment discontinuation occurred in 192 (4.9%) women in the PROLIA group and 202 (5.2%) women in

the placebo group. The 3 most common adverse events leading to treatment discontinuation were breast cancer (including patients with a history of breast cancer) (20 [0.5%] PROLIA, 10 [0.3%] placebo), back pain (6 [0.2%] PROLIA, 10 [0.3%] placebo), and constipation (6 [0.2%] PROLIA, 6 [0.2%] placebo). Cardiac disorders leading to discontinuation were reported in 14 patients (0.4%) in the PROLIA group and 3 patients (< 0.1%) in the placebo group.

Adverse events reported in  $\geq 1\%$  of postmenopausal women with osteoporosis are shown in Table 1.

**Table 1. Adverse Events Occurring in  $\geq 1\%$  of Patients with Postmenopausal Osteoporosis**

<b>SYSTEM ORGAN CLASS Preferred Term</b>	<b>PROLIA (N = 3886) n (%)</b>	<b>Placebo (N = 3876) n (%)</b>
<b>BLOOD AND LYMPHATIC SYSTEM DISORDERS</b>		
Anemia	129 (3.3)	107 (2.8)
<b>CARDIAC DISORDERS</b>		
Angina pectoris	101 (2.6)	87 (2.2)
Atrial fibrillation	79 (2.0)	77 (2.0)
Palpitations	59 (1.5)	59 (1.5)
Cardiac failure	53 (1.4)	38 (1.0)
Arrhythmia	41 (1.1)	41 (1.1)
<b>EAR AND LABYRINTH DISORDERS</b>		
Vertigo	195 (5.0)	187 (4.8)
Tinnitus	35 (0.9)	55 (1.4)
<b>ENDOCRINE DISORDERS</b>		
Hypothyroidism	62 (1.6)	59 (1.5)
<b>EYE DISORDERS</b>		
Cataract	229 (5.9)	253 (6.5)
Glaucoma	59 (1.5)	64 (1.7)
Conjunctivitis	48 (1.2)	59 (1.5)
<b>GASTROINTESTINAL DISORDERS</b>		
Constipation	355 (9.1)	361 (9.3)
Diarrhea	228 (5.9)	236 (6.1)
Dyspepsia	178 (4.6)	212 (5.5)
Nausea	178 (4.6)	193 (5.0)
Abdominal pain	146 (3.8)	149 (3.8)
Abdominal pain upper	129 (3.3)	111 (2.9)
Gastritis	99 (2.5)	109 (2.8)
Vomiting	91 (2.3)	93 (2.4)
Flatulence	84 (2.2)	53 (1.4)
Gastroesophageal reflux disease	80 (2.1)	66 (1.7)
Hemorrhoids	55 (1.4)	50 (1.3)
Hiatus hernia	49 (1.3)	56 (1.4)

**Table 1. Adverse Events Occurring in  $\geq 1\%$  of Patients with Postmenopausal Osteoporosis**

<b>SYSTEM ORGAN CLASS Preferred Term</b>	<b>PROLIA (N = 3886) n (%)</b>	<b>Placebo (N = 3876) n (%)</b>
<b>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</b>		
Edema peripheral	189 (4.9)	155 (4.0)
Fatigue	115 (3.0)	127 (3.3)
Asthenia	90 (2.3)	73 (1.9)
Noncardiac chest pain	84 (2.2)	90 (2.3)
Pain	47 (1.2)	55 (1.4)
Pyrexia	45 (1.2)	40 (1.0)
<b>HEPATOBIILIARY DISORDERS</b>		
Cholelithiasis	52 (1.3)	69 (1.8)
<b>INFECTIONS AND INFESTATIONS</b>		
Nasopharyngitis	563 (14.5)	600 (15.5)
Influenza	331 (8.5)	335 (8.6)
Bronchitis	301 (7.7)	301 (7.8)
Urinary tract infection	245 (6.3)	253 (6.5)
Cystitis	228 (5.9)	225 (5.8)
Upper respiratory tract infection	190 (4.9)	167 (4.3)
Pneumonia	152 (3.9)	150 (3.9)
Sinusitis	101 (2.6)	121 (3.1)
Pharyngitis	91 (2.3)	78 (2.0)
Gastroenteritis	81 (2.1)	94 (2.4)
Herpes zoster	79 (2.0)	72 (1.9)
Lower respiratory tract infection	69 (1.8)	86 (2.2)
Viral infection	66 (1.7)	72 (1.9)
Rhinitis	63 (1.6)	84 (2.2)
Respiratory tract infection	55 (1.4)	69 (1.8)
Ear infection	43 (1.1)	21 (0.5)
Tooth infection	26 (0.7)	41 (1.1)
<b>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</b>		
Fall	205 (5.3)	250 (6.4)
Contusion	162 (4.2)	192 (5.0)
Radius fracture	104 (2.7)	116 (3.0)
Joint sprain	60 (1.5)	65 (1.7)
Procedural pain	57 (1.5)	54 (1.4)
Humerus fracture	42 (1.1)	49 (1.3)
Rib fracture	40 (1.0)	33 (0.9)
Ulna fracture	37 (1.0)	39 (1.0)
Foot fracture	34 (0.9)	39 (1.0)
Lumbar vertebral fracture	25 (0.6)	72 (1.9)
Thoracic vertebral fracture	22 (0.6)	53 (1.4)
<b>INVESTIGATIONS</b>		
Weight decreased	41 (1.1)	49 (1.3)

**Table 1. Adverse Events Occurring in  $\geq 1\%$  of Patients with Postmenopausal Osteoporosis**

<b>SYSTEM ORGAN CLASS</b> <b>Preferred Term</b>	<b>PROLIA</b> <b>(N = 3886)</b> <b>n (%)</b>	<b>Placebo</b> <b>(N = 3876)</b> <b>n (%)</b>
<b>METABOLISM AND NUTRITION DISORDERS</b>		
Hypercholesterolemia	280 (7.2)	236 (6.1)
Diabetes mellitus	62 (1.6)	58 (1.5)
Hyperlipidemia	45 (1.2)	35 (0.9)
<b>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</b>		
Back pain	1347 (34.7)	1340 (34.6)
Arthralgia	784 (20.2)	782 (20.2)
Pain in extremity	453 (11.7)	430 (11.1)
Osteoarthritis	436 (11.2)	442 (11.4)
Musculoskeletal pain	297 (7.6)	291 (7.5)
Muscle spasms	167 (4.3)	182 (4.7)
Bone pain	142 (3.7)	117 (3.0)
Neck pain	129 (3.3)	136 (3.5)
Myalgia	114 (2.9)	94 (2.4)
Spinal osteoarthritis	82 (2.1)	64 (1.7)
Musculoskeletal chest pain	61 (1.6)	63 (1.6)
Tendonitis	56 (1.4)	47 (1.2)
Joint swelling	55 (1.4)	66 (1.7)
Arthritis	48 (1.2)	53 (1.4)
<b>NERVOUS SYSTEM DISORDERS</b>		
Headache	237 (6.1)	258 (6.7)
Dizziness	217 (5.6)	218 (5.6)
Sciatica	178 (4.6)	149 (3.8)
Syncope	67 (1.7)	71 (1.8)
Paraesthesia	63 (1.6)	56 (1.4)
Memory impairment	52 (1.3)	37 (1.0)
<b>PSYCHIATRIC DISORDERS</b>		
Depression	213 (5.5)	221 (5.7)
Insomnia	126 (3.2)	122 (3.1)
Anxiety	123 (3.2)	123 (3.2)
<b>RENAL AND URINARY DISORDERS</b>		
Urinary incontinence	39 (1.0)	40 (1.0)
Renal cyst	23 (0.6)	39 (1.0)
<b>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</b>		
Cough	224 (5.8)	238 (6.1)
Dyspnea	93 (2.4)	105 (2.7)
Asthma	66 (1.7)	65 (1.7)
Pharyngolaryngeal pain	52 (1.3)	67 (1.7)
Chronic obstructive pulmonary disease	38 (1.0)	39 (1.0)

**Table 1. Adverse Events Occurring in  $\geq 1\%$  of Patients with Postmenopausal Osteoporosis**

<b>SYSTEM ORGAN CLASS</b>	<b>PROLIA</b>	<b>Placebo</b>
<b>Preferred Term</b>	<b>(N = 3886)</b>	<b>(N = 3876)</b>
	<b>n (%)</b>	<b>n (%)</b>
<b>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</b>		
Rash	96 (2.5)	79 (2.0)
Pruritus	87 (2.2)	82 (2.1)
Eczema	50 (1.3)	25 (0.6)
Alopecia	31 (0.8)	41 (1.1)
<b>VASCULAR DISORDERS</b>		
Hypertension	614 (15.8)	636 (16.4)
Varicose vein	58 (1.5)	60 (1.5)
Hematoma	38 (1.0)	51 (1.3)

N = Number of subjects who received  $\geq 1$  dose of investigational product

n = Number of subjects reporting  $\geq 1$  event

Includes only treatment-emergent adverse events

### Less Common Clinical Trial Adverse Reactions\* (< 1%)

**MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS:** Arthralgia, Muscle spasms, Pain in extremity, Bone pain, Myalgia, Musculoskeletal stiffness, Musculoskeletal pain, Osteoarthritis, Neck pain, Exostosis, Joint swelling, Muscle fatigue, Limb discomfort, Tendonitis, Joint stiffness, Muscular weakness, Nodule on extremity, Fistula, Groin pain, Joint ankylosis, Limb deformity, Muscle hemorrhage, Rheumatoid arthritis, Spinal deformity, Spondylitis, Polymyalgia rheumatica, Sensation of heaviness, Arthritis, Bone callus excessive, Foot deformity, Muscle atrophy, Osteitis, Renal rickets, Resorption bone increased, Synovitis, Tendon pain, Tenosynovitis

**GASTROINTESTINAL DISORDERS:** Nausea, Constipation, Diarrhea, Vomiting, Abdominal pain, Flatulence, Abdominal pain upper, Dry mouth, Gastritis, Dyspepsia, Stomach discomfort, Abdominal distension, Abdominal discomfort, Abdominal pain lower, Coeliac disease, Faecalith, Frequent bowel movements, Gastric ulcer, Gastritis erosive, Gastroesophageal reflux disease, Gingivitis, Glossodynia, Hemorrhoids, Irritable bowel syndrome, Oral cavity fistula, Pancreatitis, Pancreatitis acute, Rectal hemorrhage, Aphthous stomatitis, Change of bowel habit, Enterocolitis, Gastroduodenitis, Gastrointestinal hemorrhage, Lip swelling, Melaena, Oesophageal spasm, Rectal prolapse, Reflux oesophagitis, Tongue ulceration

**INFECTIONS AND INFESTATIONS:** Nasopharyngitis, Respiratory tract infection, Upper respiratory tract infection, Influenza, Urinary tract infection, Rhinitis, Lower respiratory tract infection, Pneumonia, Bronchitis, Cystitis, Sinusitis, Herpes zoster, Oral herpes, Pharyngitis, Herpes virus infection, Tinea pedis, Viral infection, Chlamydial infection, Eczema infected, Gastroenteritis viral, Herpes ophthalmic, Laryngitis, Liver abscess, Lung infection, Viremia, Borrelia infection, Chronic sinusitis, Diverticulitis, Furuncle, Genital infection fungal, Gingival infection, Hematoma infection, Helicobacter infection, Herpes simplex, Sialoadenitis, Tracheitis

**NERVOUS SYSTEM DISORDERS:** Headache, Dizziness, Paraesthesia, Lethargy, Somnolence, Hypoaesthesia, Ischemic stroke, Dysgeusia, Sciatica, Tremor, Parosmia, Syncope, Transient ischemic attack, Disturbance in attention, Epilepsy, Freezing phenomenon, Global amnesia, Guillain-Barre syndrome, Head discomfort, Hemicephalalgia, Hypotonia, Poor quality sleep, Trigeminal neuralgia, Hypersomnia, Loss of consciousness, Memory impairment, Ageusia, Amnesia, Anosmia, Dyskinesia, Formication, Intercostal neuralgia, Migraine, Muscle contractions involuntary, Neuritis cranial, Parkinson's disease, Parkinsonism, Restless legs syndrome

**GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS:** Asthenia, Fatigue, Injection site pain, Edema peripheral, Injection site erythema, Pain, Influenza like illness, Injection site irritation, Feeling hot, Malaise, Injection site bruising, Injection site reaction, Injection site hematoma, Injection site rash, Pyrexia, Noncardiac chest pain, Peripheral coldness, Chills, Injection site warmth, Chest discomfort, Feeling cold, Gait disturbance, Hernia, Impaired healing, Injection site discomfort, Injection site mass, Injection site swelling, Irritability, Injection site pruritus, Fat tissue increased, Injection site scab, Thirst

**SKIN AND SUBCUTANEOUS TISSUE DISORDERS:** Pruritus, Rash, Alopecia, Hyperhidrosis, Eczema, Dermatitis allergic, Erythema, Dry skin, Rash macular, Rash pruritic, Onychomadesis, Ecchymosis, Pruritus generalised, Dermatitis, Rosacea, Subcutaneous nodule, Blister, Dermatitis atopic, Hair growth abnormal, Heat rash, Hyperkeratosis, Lichen planus, Nail disorder, Psoriasis, Rash generalised, Skin exfoliation, Skin warm, Urticaria, Acne, Night sweats, Pigmentation disorder, Purpura, Rash maculo-papular, Skin lesion, Skin nodule, Skin wrinkling, Swelling face, Vasculitic rash

**VASCULAR DISORDERS:** Hypertension, Hot flush, Aortic calcification, Deep vein thrombosis, Flushing, Hematoma, Varicose vein, Arteriosclerosis, Aortic stenosis, Orthostatic hypotension, Peripheral ischemia, Vasculitis, Hypotension, Thrombophlebitis, Hypertensive crisis, Venous thrombosis

**RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS:** Cough, Pharyngolaryngeal pain, Dyspnea, Dysphonia, Nasal congestion, Epistaxis, Rhinorrhea, Pulmonary embolism, Asthma, Dyspnea exertional, Nocturnal dyspnea, Sinus congestion, Sneezing, Vasomotor rhinitis, Acute pulmonary edema, Nasal dryness, Pleurisy, Productive cough, Rhinitis allergic

**CARDIAC DISORDERS:** Palpitations, Angina pectoris, Cardiac failure, Arrhythmia, Acute myocardial infarction, Extrasystoles, Ventricular extrasystoles, Atrial fibrillation, Myocardial infarction, Cardiac failure chronic, Coronary artery disease, Hypertensive cardiomyopathy, Ischemic cardiomyopathy, Supraventricular extrasystoles, Tachycardia, Mitral valve incompetence, Tachyarrhythmia

**EYE DISORDERS:** Cataract, Glaucoma, Conjunctivitis allergic, Dry eye, Ocular discomfort, Eyelid pain, Lacrimation increased, Visual disturbance, Vitreous disorder, Conjunctivitis, Eye pain, Arteriosclerotic retinopathy, Blepharitis, Blepharospasm, Eyelids pruritus, Lacrimal gland enlargement, Photophobia, Vision blurred, Vitreous hemorrhage

**EAR AND LABYRINTH DISORDERS:** Vertigo, Ear pain, Ear discomfort, Tinnitus, Cerumen impaction, Ear congestion, Ear disorder, Otosalpingitis, Tympanic membrane perforation

**NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS):** Breast cancer, Ovarian cancer, Basal cell carcinoma, Benign neoplasm of thyroid gland, Benign soft tissue neoplasm, Cerebellar tumour, Cervix carcinoma, Lipoma, Multiple myeloma, Uterine leiomyoma, Benign breast neoplasm, Acral lentiginous melanoma stage unspecified, Adenocarcinoma, Benign bone neoplasm, Benign neoplasm, Bladder neoplasm, Colon cancer, Diffuse large B-cell lymphoma recurrent, Hemangioma, Hemangioma of liver, Lipoma of breast, Melanocytic naevus

**BLOOD AND LYMPHATIC SYSTEM DISORDERS:** Eosinophilia, Leukopenia, Thrombocytopenia, Anemia, Leukocytosis, Lymphadenopathy, Lymphocytosis, Neutrophilia, Pancytopenia, Neutropenia, Bone marrow failure, Lymphopenia

**INVESTIGATIONS:** Weight decreased, Blood pressure increased, Alanine aminotransferase increased, Coagulation time shortened, Red blood cell sedimentation rate increased, Blood chloride decreased, Blood sodium decreased, Weight increased, Cardiac murmur, Aspartate aminotransferase increased, Hemoglobin decreased, International normalised ratio increased, Platelet count decreased, Red blood cell count decreased, Rheumatoid factor positive

**METABOLISM AND NUTRITION DISORDERS:** Hypercalcemia, Anorexia, Hypercholesterolemia, Decreased appetite, Diabetes mellitus, Glucose tolerance impaired, Hypomagnesemia

**PSYCHIATRIC DISORDERS:** Depression, Depressed mood, Insomnia, Apathy, Dysthymic disorder, Sleep disorder, Restlessness

**RENAL AND URINARY DISORDERS:** Dysuria, Hematuria, Nephrolithiasis, Acute prerenal failure, Polyuria, Urge incontinence, Urine abnormality, Pollakiuria, Nephrosclerosis, Nocturia, Proteinuria, Renal impairment, Urine odour abnormal

**REPRODUCTIVE SYSTEM AND BREAST DISORDERS:** Breast pain, Vulvovaginal pruritus, Breast disorder, Vaginal hemorrhage, Breast discomfort, Vulvovaginal dryness, Breast mass, Fibrocystic breast disease, Breast necrosis, Breast tenderness, Vulvovaginal burning sensation

**ENDOCRINE DISORDERS:** Goitre, Hyperthyroidism, Hypothyroidism, Hyperparathyroidism



**INJURY, POISONING AND PROCEDURAL COMPLICATIONS:** Thoracic vertebral fracture, Clavicle fracture, Femoral neck fracture, Post procedural hemorrhage, Lumbar vertebral fracture, Fall, Anastomotic ulcer hemorrhage, Contusion, Humerus fracture, Ilium fracture, Joint dislocation, Joint sprain, Post concussion syndrome, Radius fracture, Scratch

**HEPATOBIILIARY DISORDERS:** Liver disorder, Hepatic cyst, Cholecystitis, Cholelithiasis

**IMMUNE SYSTEM DISORDERS:** Hypersensitivity, Drug hypersensitivity

**CONGENITAL, FAMILIAL AND GENETIC DISORDERS:** Familial tremor

**SURGICAL AND MEDICAL PROCEDURES:** Fistula repair

*\*Terms designated by investigators as related to study drugs*

## Hypocalcemia

In postmenopausal women with osteoporosis in Study 1, declines of serum calcium concentrations to less than the normal range were reported in 15 (0.4%) women in the placebo group and 63 (1.6%) women in the PROLIA group. Declines of serum calcium concentrations to < 7.5 mg/dL (< 1.88 mmol/L) were reported in 2 (< 0.1%) women in the placebo group and 1 (< 0.1%) in the PROLIA group. In clinical studies, subjects with impaired renal function were more likely to have greater reductions in serum calcium levels compared to subjects with normal renal function. In a study of 55 patients with varying degrees of renal function who did not receive calcium and vitamin D supplementation, symptomatic hypocalcemia or serum calcium levels < 7.5 mg/dL was observed in 5 subjects, including no subjects in the normal renal function group, 10% (1 out of 10) of subjects in the CrCL 50 to 80 mL/min group, 29% (2 out of 7) of subjects in the CrCL < 30 mL/min group, and 29% (2 out of 7) of subjects in the hemodialysis group (see **WARNINGS AND PRECAUTIONS**).

## Infections

Receptor activator of nuclear factor kappa-B ligand (RANKL) is expressed on activated T and B lymphocytes and in lymph nodes. Therefore, a RANKL inhibitor such as PROLIA may increase the risk of infection. In the clinical study of 7808 postmenopausal women with osteoporosis, the incidence of infections resulting in death was 6 (0.2%) in both placebo and PROLIA treatment groups. The incidence of nonfatal serious infections was 3.3% (n = 128) in the placebo group and 4.0% (n = 154) in the PROLIA group. Hospitalizations due to serious infections in the abdomen 28 (0.7%) placebo vs. 36 (0.9%) PROLIA, urinary tract 20 (0.5%) placebo vs. 29 (0.7%) PROLIA, and ear 0 (0.0%) placebo vs. 5 (0.1%) PROLIA were reported. Endocarditis was reported in 0 (0.0%) placebo patients and 3 (0.1%) patients receiving PROLIA.

Overall skin infections leading to hospitalization were reported more frequently in patients treated with PROLIA (2 [< 0.1%] placebo vs. 15 [0.4%] PROLIA) among women with postmenopausal osteoporosis in Study 1. These events were predominantly comprised of erysipelas (0 [0%] placebo and 7 [0.2%] PROLIA) and cellulitis (1 [< 0.1%] placebo and 6 [0.2%] PROLIA) (see **WARNINGS AND PRECAUTIONS**).

The overall incidence of infections was similar between the PROLIA and placebo groups (2055 [52.9%] PROLIA, 2108 [54.4%] placebo). The incidence of specific infection types was as follows: urinary tract infections (245 [6.3%] PROLIA, 253 [6.5%] placebo), upper respiratory infections (190 [4.9%] PROLIA, 167 [4.3%] placebo), ear infections (43 [1.1%] PROLIA, 21 [0.5%] placebo), and diverticulitis (28 [0.7%] PROLIA, 22 [0.6%] placebo).

There was no imbalance in the reporting of opportunistic infections (4 [0.1%] PROLIA, 3 [0.1%] placebo).

### **Dermatologic**

A significantly higher number of patients treated with PROLIA developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% (n = 316) of placebo and 10.8% (n = 421) of PROLIA group (p < 0.0001). Most of these events were not specific to the injection site (see **WARNINGS AND PRECAUTIONS, Dermatologic**).

### **Osteonecrosis of the Jaw (ONJ)**

ONJ has been reported rarely in the open-label osteoporosis clinical trial program in patients treated with PROLIA (see **WARNINGS AND PRECAUTIONS**).

### **Atypical Femoral Fracture**

In the osteoporosis clinical trial program, atypical femoral fractures were reported in patients treated with PROLIA (see **WARNINGS AND PRECAUTIONS**).

### **Multiple Vertebral Fractures (MVF) Following Discontinuation of PROLIA Treatment**

In the osteoporosis clinical trial program, MVF were reported in patients following discontinuation of treatment with PROLIA, particularly in those with a history of vertebral fracture.

### **Cardiovascular Disorders**

The incidence of positively adjudicated cardiovascular serious adverse events was 186 (4.8%) PROLIA and 178 (4.6%) placebo, with a hazard ratio (95% confidence interval) of 1.02 (0.83, 1.25). Adjudicated cardiovascular events were further sub-categorized as follows: cardiovascular death, acute coronary syndrome, stroke/transient ischemic attack, congestive heart failure, other vascular event, and arrhythmia. The incidence of these subcategories was 23 (0.6%) PROLIA and 31 (0.8%) placebo for cardiovascular death, 47 (1.2%) PROLIA and 39 (1.0%) placebo for acute coronary syndrome, 56 (1.4%) PROLIA and 54 (1.4%) placebo for stroke/transient ischemic attack, 27 (0.7%) PROLIA and 22 (0.6%) placebo for congestive heart failure, 31 (0.8%) PROLIA and 30 (0.8%) placebo for other vascular event, and 52 (1.3%) PROLIA and 45 (1.2%) placebo for arrhythmia.

### **Fracture Healing**

Delayed fracture healing of nonvertebral fractures was reported in 2 out of 303 (0.7%) subjects in the PROLIA group (3 out of 386 [0.8%] nonvertebral fractures) and 2 out of 364 (0.5%) subjects in the placebo group (2 out of 465 [0.4%] nonvertebral fractures). In addition, nonunion of nonvertebral fractures was reported in 0 out of 303 (0%) subjects in the PROLIA group (0 out of 386 [0%] nonvertebral fractures) and 1 out of 364 (0.3%) subjects in the placebo group (1 out of 465 [0.2%] nonvertebral fractures). For fractures that occurred near the final study closure, additional follow-up after study closure identified 2 additional subjects in the placebo group and 0 in the PROLIA group with delayed fracture healing. Of the subjects with a distal radius fracture, 1 out of 104 (1.0%) subjects in the PROLIA group (1 out of 106 [0.9%] distal radius

fractures) and 0 out of 116 (0%) subjects in the placebo group (0 out of 118 [0%] distal radius fractures) had delayed fracture healing.

### **Malignancies**

The overall incidence of new malignancies was 188 (4.8%) in the PROLIA and 166 (4.3%) in the placebo groups. The most common malignancies ( $\geq 0.2\%$ ) included: breast cancer (28 [0.7%] PROLIA, 26 [0.7%] placebo), colon cancer (11 [0.3%] PROLIA, 8 [0.2%] placebo), lung neoplasm malignant (9 [0.2%] PROLIA, 9 [0.2%] placebo), gastric cancer (7 [0.2%] PROLIA, 3 [0.1%] placebo), pancreatic carcinoma (7 [0.2%] PROLIA, 3 [0.1%] placebo), squamous cell carcinoma of skin (6 [0.2%] PROLIA, 8 [0.2%] placebo), and recurrent breast cancer (6 [0.2%] PROLIA, 2 [0.1%] placebo). Other malignancies reported include: thyroid cancer (2 [0.1%] PROLIA, 0 [0%] placebo), carcinoid of the stomach (1 [ $< 0.1\%$ ] PROLIA, 0 [0%] placebo), uterine cancer (3 [0.1%] PROLIA, 1 [ $< 0.1\%$ ] placebo), ovarian cancer metastatic (2 [0.1%] PROLIA, 0 [0%] placebo), ovarian epithelial cancer (2 [0.1%] PROLIA, 0 [0%] placebo), vulval cancer (2 [0.1%] PROLIA, 0 [0%] placebo), and lentigo maligna stage unspecified (3 [0.1%] PROLIA, 0 [0%] placebo). A causal relationship to drug exposure has not been established.

### **Hypersensitivity Reactions**

The incidence of adverse drug reactions potentially associated with hypersensitivity was 50 (1.3%) in the PROLIA group and 50 (1.3%) in the placebo group. The most common adverse event potentially associated with hypersensitivity was urticaria (27 [0.7%] PROLIA, 27 [0.7%] placebo).

### **Pancreatitis**

Pancreatitis was reported in 4 patients (0.1%) in the placebo and 8 patients (0.2%) in the PROLIA groups. Of these reports, one patient in the placebo group and all 8 patients in the PROLIA group had serious events including 2 deaths in the PROLIA group. Several patients had a prior history of pancreatitis or a confounding event (eg, gallstones). The time from product administration to event occurrence was variable.

### **Laboratory Abnormalities**

The most frequent laboratory abnormalities were changes in serum calcium with compensatory physiological changes in serum phosphorus. The median percent change from baseline (interquartile range) at month 1 for serum calcium was -2.1% (-5.2% to 1.0%) for PROLIA and 1.0% (-2.0% to 3.2%) for placebo. The median percent change from baseline (interquartile range) at month 1 for serum phosphorus was -8.3% (-15.8% to 0%) for PROLIA and 0% (-5.6% to 8.3%) for placebo. Alkaline phosphatase was also reduced, by month 6, which reflects reduced osteoclast activity in bone, with a decrease from baseline of 25% in PROLIA subjects compared to 3% to 8% in placebo subjects.

Serum phosphorous levels were between 2.0 and 2.5 mg/dL in 2.0% (n = 82) of patients in the placebo group and 7.0% (n = 263) of patients in the denosumab group. Decrease in platelet levels to between 50,000/mm<sup>3</sup> and 75,000/mm<sup>3</sup> was reported at 0.2% (n = 7) in the placebo group and 0.4% (n = 14) in the denosumab group, and decrease in platelet levels to  $< 25,000/\text{mm}^3$  was reported at  $< 0.1\%$  (n = 2) in the placebo group and at 0.1% (n = 4) in the denosumab group. Increase in aspartate aminotransferase (AST) levels to between 1.0 and 2.5 x the upper limit of

normal (ULN) was reported at 5.0% (n = 206) in the placebo group and 7.0% (n = 264) in the denosumab group, and increase in alanine aminotransferase levels (ALT) to between 2.5 and 5.0 x ULN were reported at 0.5% (n = 21) in the placebo group and 1.0% (n = 37) in the denosumab group. Increase in total bilirubin value to between 3.0 and 10.0 x ULN was reported at 0.0% (n = 0) in the placebo group and 0.1% (n = 5) in the denosumab group.

### **Long Term Safety in Postmenopausal Osteoporosis**

The safety of PROLIA was assessed in clinical studies of up to 10 years in duration.

A total of 4550 patients who completed Study 1 (N = 7808) enrolled into a 7-year, multinational, multicenter, open label, single-arm extension study to evaluate the long-term safety and efficacy of PROLIA. All patients in the extension study were to receive PROLIA every 6 months as a single 60 mg SC dose, as well as daily calcium (1 g) and vitamin D (at least 400 IU).

Based on data from 7 years of the extension study for patients who received PROLIA in Study 1 and continued on therapy (years 4 through 10 of PROLIA treatment; N = 2343), the overall subject incidence rates of adverse events and serious adverse events reported (event rates per 100 patient-years) were similar to that observed in the initial 3 years of Study 1. For patients who crossed over to PROLIA from placebo in Study 1 (N = 2206), the overall subject incidence rates of adverse events and serious adverse events reported (event rates per 100 patient-years) were also similar to that observed in the first 3 years of Study 1. Events of osteonecrosis of the jaw and atypical femoral fractures have been observed.

A summary of the safety results are provided in the following Table 2.

**Table 2. Patient-year-adjusted Adverse Events Rates (per 100 Patient-years)**

	Placebo	PROLIA		
	Study 1 Years 1-3 N = 3883 (Patient-year = 10738.8) Rate (Events)	Study 1 Years 1-3 N = 3879 (Patient-year = 10805.6) Rate (Events)	Cross-Over Extension Years 1-7 N = 2206 (Patient-year = 12082.7) Rate (Events)	Long-Term Extension Years 4-10 N = 2343 (Patient-year = 12798.0) Rate (Events)
<b>All Adverse Events (AE)</b>	237.3 (25482)	235.1 (25406)	174.5 (21083)	174.8 (22374)
<b>Most Common AEs</b>				
Arthralgia	10.2 (1093)	10.3 (1112)	6.3 (765)	6.1 (778)
Back Pain	19.1 (2052)	19.0 (2053)	5.9 (710)	5.3 (676)
Hypertension	6.7 (723)	6.5 (701)	5.0 (604)	4.9 (629)
Nasopharyngitis	7.3 (782)	7.0 (751)	4.7 (565)	4.5 (576)
Osteoarthritis	5.5 (587)	4.8 (519)	4.4 (536)	4.7 (602)
Pain in extremity	5.2 (555)	5.6 (600)	2.8 (338)	3.0 (389)
<b>Serious Adverse Events</b>	16.4 (1758)	17.3 (1870)	17.2 (2080)	17.3 (2217)
<b>Deaths</b>	0.9 (92)	0.7 (72)	0.8 (102)	0.9 (111)
<b>Clinically Significant AEs</b>				
Hypocalcemia	<0.1 (3)	0 (0)	<0.1 (10)	<0.1 (6)
Osteonecrosis of the Jaw	0 (0)	0 (0)	<0.1 (6)	<0.1 (7)
Atypical Femoral Fracture	0 (0)	0 (0)	<0.1 (1)	<0.1 (1)
Serious Infections	1.4 (152)	1.8 (191)	1.9 (230)	2.0 (253)
Infections	40.9 (4396)	40.6 (4385)	32.7 (3948)	33.6 (4296)
Malignancies	1.8 (191)	1.9 (210)	2.4 (291)	2.2 (287)
Delayed Fracture Healing	<0.1 (2)	<0.1 (1)	0 (0.0)	<0.1 (1)
Pancreatitis	<0.1 (3)	<0.1 (9)	<0.1 (5)	<0.1 (11)
Eczema	0.7 (77)	1.3 (139)	1.1 (129)	1.0 (131)
Hypersensitivity	3.2 (347)	4.2 (457)	3.0 (359)	2.9 (370)

Patient-year = Total patient-years of follow-up, including time through the end of study date; Events = Number of events;

Rate = Event rate per 100 patient-years ([Events / Patient-year] \* 100)

N = Number of patients who received ≥ 1 dose of investigational product. Treatment groups in Extension are based on the original randomized assignments in the 20030216 study.

Multiple occurrences of the same event for a patient are counted as multiple events. Includes only treatment-emergent adverse events.

## **Other Studies in Postmenopausal Women**

The safety of PROLIA was assessed in a 2-year, randomized, double-blind, placebo-controlled, multinational study of 332 postmenopausal women aged 43 to 83 years with low bone mass (Study 2). A total of 165 women received placebo and 164 women received PROLIA administered once every 6 months as a single 60 mg SC dose. All women received calcium (at least 1000 mg) and vitamin D (at least 400 IU) supplementation per day. The incidence of adverse events was 156 (95%) in the PROLIA group and 157 (95%) in the placebo group. The incidence of serious adverse events was 11% (n = 18) in the PROLIA group and 6% (n = 9) in the placebo group. No subject died during the study. The 3 most common adverse events were arthralgia (26% (n = 43) PROLIA vs. 26% (n = 42) placebo), nasopharyngitis (22% (n = 36) PROLIA vs. 19% (n = 32) placebo), and back pain (20% (n = 33) PROLIA vs. 21% (n = 34) placebo).

Two randomized, double-blind, active-controlled studies (Study 3 and Study 4) assessed the safety of PROLIA compared with alendronate. In Study 3, a total of 1179 postmenopausal women with low bone mass who were treatment naive (593 randomized to PROLIA 60 mg SC once every 6 months, 586 randomized to alendronate tablets 70 mg once weekly) received investigational product and were evaluated for safety. All women received daily supplemental calcium (at least 1000 mg) and vitamin D (at least 400 IU). The incidence of adverse events was 81% (n = 480) in the PROLIA group and 82% (n = 482) in the alendronate group. The incidence of serious adverse events was 6% (n = 34) in the PROLIA group and 6% (n = 37) in the alendronate group. One subject in each treatment group died during the study. The 3 most frequent adverse events were arthralgia (13% (n = 75) PROLIA vs. 10% (n = 56) alendronate), nasopharyngitis (8% (n = 45) PROLIA vs. 7% (n = 43) alendronate), and back pain (7% (n = 42) PROLIA vs. 10% (n = 56) alendronate).

In Study 4, a total of 502 postmenopausal women with low bone mass who were being treated with alendronate for a median duration of 3 years (253 PROLIA 60 mg SC every 6 months, 249 alendronate tablets 70 mg once weekly) received investigational product and were evaluated for safety. All women received daily supplemental calcium (at least 1000 mg) and vitamin D (at least 400 IU). The incidence of adverse events was 78% (n = 197) in the PROLIA group and 79% (n = 196) in the alendronate group. The incidence of serious adverse events was 6% (n = 15) in the PROLIA group and 6% (n = 16) in the alendronate group. One subject in the PROLIA treatment group died during the study. The 3 most frequent adverse events were nasopharyngitis (13% (n = 34) PROLIA vs. 11% (n = 27) alendronate), back pain (11% (n = 27) PROLIA vs. 12% (n = 29) alendronate), and arthralgia (6% (n = 15) PROLIA vs. 10% (n = 26) alendronate).

The safety profile of denosumab in women with postmenopausal osteoporosis was consistent with results in these 3 studies among women with postmenopausal bone loss. No notable differences were observed between those women who had received prior osteoporosis therapy versus those who had not received prior osteoporosis therapy (ie, alendronate).

## **Immunogenicity**

Denosumab is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with PROLIA. More than 13000 patients were screened for binding antibodies using a sensitive electrochemiluminescent bridging immunoassay. Less than 1% (55

out of 8113) of patients treated with PROLIA for up to 5 years tested positive for antibodies (including pre-existing, transient, and developing antibodies). The patients that tested positive for binding antibodies were further evaluated for neutralizing antibodies using a chemiluminescent cell-based *in vitro* biological assay and none of them tested positive. No evidence of altered pharmacokinetic profile, toxicity profile, or clinical response was associated with binding antibody development.

The detection of antibody formation is dependent on the sensitivity and specificity of the assay. The observed incidence of antibody positivity in an assay may be influenced by factors such as sample handling, concomitant medications, and underlying disease. For these reasons, comparison of antibodies to denosumab with the incidence of antibodies to other products may be misleading.

### **Treatment to Increase Bone Mass in Men with Osteoporosis at High Risk for Fracture**

The safety of PROLIA in the treatment of men with osteoporosis was assessed in a randomized, double-blind, placebo-controlled study; a 1 year double-blind phase followed by a 1 year open-label extension.

During the double-blind phase, a total of 242 men (121 PROLIA, 121 placebo) were enrolled; a total of 120 men were exposed to placebo and 120 men were exposed to PROLIA administered subcutaneously once every 6 months as a single 60 mg dose. All men were instructed to take at least 1000 mg of calcium and 800 IU of vitamin D supplementation per day.

The most common adverse reactions ( $\geq 5\%$  and more common than placebo) reported in men with osteoporosis were: back pain (10 [8.3%] PROLIA, 8 [6.7%] placebo), arthralgia (8 [6.7%] PROLIA, 7 [5.8%] placebo), and nasopharyngitis (8 [6.7%] PROLIA, 7 [5.8%] placebo).

There were 2 deaths during the clinical trial: 1 (0.8%, acute myocardial infarction) in the PROLIA group and 1 (0.8%, basilar artery thrombosis) in the placebo group.

There were 16 serious adverse events (SAEs) in 11 patients (9.2%) in the PROLIA group: 6 cardiovascular (2 arterial thrombosis limb, 2 myocardial infarction, 1 peripheral ischaemia, 1 vascular pseudoaneurysm), 3 prostate cancer, and one each of: chest pain, acute pancreatitis, cholecystitis, injury, post procedural complication, road traffic accident, spinal column stenosis (severity: 3 moderate, 12 severe, and 1 fatal). In the placebo group, there were 13 SAEs in 10 patients (8.3%): 3 cardiovascular (peripheral ischaemia, atrial fibrillation, basilar artery thrombosis), 3 musculoskeletal (ligament rupture, meniscus lesion, osteoarthritis), 2 ophthalmic (retinal detachment, vitreous haemorrhage), and one each of: pancreatitis, pneumonia, prostatic adenoma, skull malformation, and cerebral haemorrhage (severity: 2 mild, 8 moderate, 2 severe, and 1 fatal).

The number (percentage) of patients who discontinued the investigational product or withdrew from the study due to adverse events was 4 patients (3.3%) with 4 events for the PROLIA group (prostate cancer, myocardial infarction, upper respiratory tract infections, and road traffic accident), vs. 0 for the placebo group.

Adverse events reported in  $\geq 1\%$  of PROLIA-treated or placebo-treated patients are shown in Table 3.

**Table 3. Adverse Events Occurring in  $\geq 1\%$  of Men with Osteoporosis  
(First 12 Months Analysis)**

<b>SYSTEM ORGAN CLASS Preferred Term</b>	<b>PROLIA (N = 120) n (%)</b>	<b>Placebo (N = 120) n (%)</b>
<b>CARDIAC DISORDERS</b>		
Angina pectoris	2 (1.7)	0 (0.0)
Arrhythmia	2 (1.7)	0 (0.0)
Atrial fibrillation	0 (0.0)	2 (1.7)
<b>EYE DISORDERS</b>		
Cataract	2 (1.7)	3 (2.5)
Conjunctivitis	0 (0.0)	2 (1.7)
<b>GASTROINTESTINAL DISORDERS</b>		
Diarrhoea	2 (1.7)	3 (2.5)
Flatulence	2 (1.7)	0 (0.0)
Gastroesophageal reflux disease	1 (0.8)	2 (1.7)
Constipation	0 (0.0)	7 (5.8)
Abdominal pain upper	0 (0.0)	3 (2.5)
Dyspepsia	0 (0.0)	2 (1.7)
Gastric polyps	0 (0.0)	2 (1.7)
Inguinal hernia	0 (0.0)	2 (1.7)
<b>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</b>		
Chest pain	2 (1.7)	1 (0.8)
Fatigue	1 (0.8)	2 (1.7)
<b>INFECTIONS AND INFESTATIONS</b>		
Nasopharyngitis	8 (6.7)	7 (5.8)
Sinusitis	2 (1.7)	1 (0.8)
Tooth infection	2 (1.7)	1 (0.8)
Upper respiratory tract infection	2 (1.7)	1 (0.8)
Influenza	1 (0.8)	4 (3.3)
Pneumonia	0 (0.0)	2 (1.7)
<b>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</b>		
Fall	2 (1.7)	2 (1.7)
Contusion	2 (1.7)	0 (0.0)
Post procedural haematoma	1 (0.8)	2 (1.7)
Procedural pain	0 (0.0)	3 (2.5)
Arthropod bite	0 (0.0)	2 (1.7)
<b>INVESTIGATIONS</b>		
Weight decreased	0 (0.0)	2 (1.7)
<b>METABOLISM AND NUTRITION DISORDERS</b>		
Hypercholesterolaemia	3 (2.5)	0 (0.0)
Hyperglycaemia	0 (0.0)	2 (1.7)
Hyponatraemia	0 (0.0)	2 (1.7)



**Table 3. Adverse Events Occurring in  $\geq 1\%$  of Men with Osteoporosis  
(First 12 Months Analysis)**

<b>SYSTEM ORGAN CLASS Preferred Term</b>	<b>PROLIA (N = 120) n (%)</b>	<b>Placebo (N = 120) n (%)</b>
<b>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</b>		
Back pain	10 (8.3)	8 (6.7)
Arthralgia	8 (6.7)	7 (5.8)
Osteoarthritis	4 (3.3)	2 (1.7)
Muscle spasms	3 (2.5)	0 (0.0)
Myalgia	2 (1.7)	5 (4.2)
Pain in extremity	2 (1.7)	3 (2.5)
Bone pain	2 (1.7)	0 (0.0)
Musculoskeletal pain	1 (0.8)	4 (3.3)
Musculoskeletal chest pain	1 (0.8)	2 (1.7)
Musculoskeletal stiffness	0 (0.0)	2 (1.7)
Spinal osteoarthritis	0 (0.0)	2 (1.7)
<b>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCLUDING CYSTS AND POLYPS)</b>		
Prostate cancer <sup>a</sup>	3 (2.5)	0 (0.0)
Prostatic adenoma	1 (0.8)	2 (1.7)
<b>NERVOUS SYSTEM DISORDERS</b>		
Dizziness	2 (1.7)	2 (1.7)
Headache	1 (0.8)	5 (4.2)
<b>RENAL AND URINARY DISORDERS</b>		
Renal cyst	0 (0.0)	2 (1.7)
<b>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</b>		
Cough	1 (0.8)	3 (2.5)
Asthma	0 (0.0)	2 (1.7)
<b>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</b>		
Rash	1 (0.8)	2 (1.7)
<b>VASCULAR DISORDERS</b>		
Arterial thrombosis limb	2 (1.7)	0 (0.0)
Hypertension	1 (0.8)	5 (4.2)

N = Number of subjects who received  $\geq 1$  dose of investigational product

n = Number of subjects reporting  $\geq 1$  event

Includes only treatment-emergent adverse events

<sup>a</sup> 2 of the prostate cancer cases were diagnosed within the first month of the patients receiving PROLIA

### **Osteonecrosis of the Jaw**

Osteonecrosis of the jaw (ONJ) has been reported in patients treated with denosumab or bisphosphonates, another class of anti-resorptive agents (see **WARNINGS AND PRECAUTIONS, Osteonecrosis of the Jaw**).

### **New Malignancies**

New malignancies were reported in 4 patients (3.3%; 3 prostate cancers, 1 basal cell carcinoma) in the PROLIA group and 0 in the placebo group.

### **Cardiac Disorders**

There were 6 patients (5.0%) with cardiac AEs (2 angina pectoris, 2 myocardial infarction and 2 arrhythmia) in the PROLIA group, and 3 patients (2.5%, 2 atrial fibrillation and 1 palpitations) in the placebo group. There were 2 patients (1.7%) with serious cardiac AEs (2 myocardial infarction) in the PROLIA group, and 1 (0.8%, atrial fibrillation) in the placebo group.

### **Fracture**

Clinical fractures were confirmed for 1 patient (0.8%) in the PROLIA group and 2 patients (1.7%) in the placebo group; new morphometric vertebral fractures were confirmed in no patients in the PROLIA group and 1 patient (0.8%) in the placebo group.

### **Laboratory Abnormalities**

PROLIA administration was associated with decreases in serum calcium. At day 15, median change from baseline in albumin-adjusted serum calcium was -1.1% in the PROLIA group and 0.0% in the placebo group. No decrease in median serum calcium was observed at months 6 and 12. No patients had Grade 3 or 4 low serum calcium values during the study.

PROLIA administration also was associated with decreases in serum phosphorus. Median change from baseline in phosphorus was (PROLIA, placebo) -6.0%, 2.9% at day 15; -4.7%, 0.0% at month 6; and 0.0%, 0.0% at month 12. No patients had Grade 3 or 4 low serum phosphorus values during the study.

### **Treatment to Increase Bone Mass in Patients Receiving ADT for Prostate Cancer**

The safety of PROLIA in the treatment of bone loss in men with nonmetastatic prostate cancer receiving ADT was assessed in a 3 year, randomized, double-blind, placebo-controlled, multinational study.

During the double-blind phase, a total of 1468 men aged 48 to 97 years were enrolled; the median age was 76 years, and 92.9% of subjects were  $\geq$  65 years of age. A total of 725 men were exposed to placebo and 731 men were exposed to PROLIA administered once every 6 months as a single 60 mg subcutaneous dose. All men were instructed to take at least 1000 mg of calcium and 400 IU of vitamin D supplementation per day.

Adverse events reported in  $\geq 5\%$  of PROLIA-treated patients receiving ADT for nonmetastatic prostate cancer, and more frequently than in the placebo-treated patients were (PROLIA vs. placebo): arthralgia (92 [12.6%] PROLIA, 80 [11.0%] placebo), back pain (81 [11.1%] PROLIA, 74 [10.2%] placebo), pain in extremity (66 [9.0%] PROLIA, 51 [7.0%] placebo), hypertension (57 [7.8%] PROLIA, 51 [7.0%] placebo), oedema peripheral (53 [7.3%] PROLIA, 48 [6.6%] placebo), nasopharyngitis (47 [6.4%] PROLIA, 45 [6.2%] placebo), dizziness (41 [5.6%] PROLIA, 31 [4.3%] placebo), musculoskeletal pain (41 [5.6%] PROLIA, 26 [3.6%] placebo), diarrhea (40 [5.5%] PROLIA, 39 [5.4%] placebo), hot flush (38 [5.2%] PROLIA, 32 [4.4%] placebo), and urinary tract infection (37 [5.1%] PROLIA, 32 [4.4%] placebo).

The incidence of SAEs was 34.6% (n = 253) in the PROLIA group and 30.6% (n = 222) in the placebo group. The 3 most common serious adverse events were myocardial infarction (14 [1.9%] PROLIA, 18 [2.5%] placebo), pneumonia (11 [1.5%] PROLIA, 11 [1.5%] placebo), and atrial fibrillation (11 [1.5%] PROLIA, 8 [1.1%] placebo). Deaths occurred in 44 subjects (6.0%) in the PROLIA group and 46 subjects (6.3%) in the placebo group.

The percentage of patients who withdrew from the study due to adverse events was 51 (7.0%) and 44 (6.1%) for the PROLIA and placebo groups, respectively.

Adverse events reported in  $\geq 1\%$  of PROLIA-treated or placebo-treated patients are shown in Table 4.

**Table 4. Adverse Events Occurring in  $\geq 1\%$  of Men with Bone Loss Associated with ADT for Nonmetastatic Prostate Cancer**

<b>SYSTEM ORGAN CLASS Preferred Term</b>	<b>PROLIA (N = 731) n (%)</b>	<b>Placebo (N = 725) n (%)</b>
<b>BLOOD AND LYMPHATIC SYSTEM DISORDERS</b>		
Anaemia	33 (4.5)	35 (4.8)
<b>CARDIAC DISORDERS</b>		
Atrial fibrillation	21 (2.9)	18 (2.5)
Angina pectoris	17 (2.3)	8 (1.1)
Coronary artery disease	15 (2.1)	17 (2.3)
Myocardial infarction	14 (1.9)	18 (2.5)
Cardiac failure congestive	13 (1.8)	18 (2.5)
Bradycardia	8 (1.1)	4 (0.6)
<b>EAR AND LABYRINTH DISORDERS</b>		
Vertigo	13 (1.8)	9 (1.2)
<b>ENDOCRINE DISORDERS</b>		
Hypothyroidism	9 (1.2)	2 (0.3)
<b>EYE DISORDERS</b>		
Cataract	34 (4.7)	9 (1.2)
<b>GASTROINTESTINAL DISORDERS</b>		
Constipation	73 (10.0)	75 (10.3)
Diarrhoea	40 (5.5)	39 (5.4)
Nausea	22 (3.0)	27 (3.7)
Abdominal pain	15 (2.1)	21 (2.9)
Gastroesophageal reflux disease	12 (1.6)	13 (1.8)
Gastritis	11 (1.5)	8 (1.1)
Inguinal hernia	11 (1.5)	4 (0.6)
Vomiting	11 (1.5)	17 (2.3)
Dyspepsia	10 (1.4)	13 (1.8)
Abdominal pain upper	9 (1.2)	12 (1.7)
Rectal haemorrhage	7 (1.0)	9 (1.2)
<b>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</b>		
Oedema peripheral	53 (7.3)	48 (6.6)
Fatigue	44 (6.0)	45 (6.2)
Asthenia	31 (4.2)	27 (3.7)
Pyrexia	11 (1.5)	10 (1.4)
Chest pain	8 (1.1)	10 (1.4)
Non-cardiac chest pain	8 (1.1)	8 (1.1)
Pain	6 (0.8)	11 (1.5)

**Table 4. Adverse Events Occurring in  $\geq 1\%$  of Men with Bone Loss Associated with ADT for Nonmetastatic Prostate Cancer**

<b>SYSTEM ORGAN CLASS Preferred Term</b>	<b>PROLIA (N = 731) n (%)</b>	<b>Placebo (N = 725) n (%)</b>
<b>HEPATOBIILIARY DISORDERS</b>		
Cholelithiasis	7 (1.0)	12 (1.7)
<b>INFECTIONS AND INFESTATIONS</b>		
Nasopharyngitis	47 (6.4)	45 (6.2)
Urinary tract infection	37 (5.1)	32 (4.4)
Upper respiratory tract infection	31 (4.2)	26 (3.6)
Bronchitis	30 (4.1)	21 (2.9)
Pneumonia	29 (4.0)	25 (3.4)
Influenza	23 (3.1)	20 (2.8)
Sinusitis	17 (2.3)	15 (2.1)
Herpes zoster	11 (1.5)	7 (1.0)
Cystitis	10 (1.4)	8 (1.1)
Diverticulitis	9 (1.2)	0 (0.0)
Cellulitis	6 (0.8)	8 (1.1)
Lower respiratory tract infection	3 (0.4)	10 (1.4)
<b>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</b>		
Fall	22 (3.0)	27 (3.7)
Contusion	16 (2.2)	11 (1.5)
Rib fracture	16 (2.2)	14 (1.9)
Procedural pain	15 (2.1)	3 (0.4)
Skin laceration	12 (1.6)	4 (0.6)
Muscle strain	10 (1.4)	6 (0.8)
Radius fracture	2 (0.3)	12 (1.7)
<b>INVESTIGATIONS</b>		
Weight decreased	10 (1.4)	10 (1.4)
Blood cholesterol increased	6 (0.8)	8 (1.1)
Cardiac murmur	4 (0.5)	11 (1.5)
<b>METABOLISM AND NUTRITION DISORDERS</b>		
Diabetes mellitus	14 (1.9)	18 (2.5)
Dehydration	12 (1.6)	5 (0.7)
Hypercholesterolaemia	12 (1.6)	9 (1.2)
Hypokalaemia	12 (1.6)	7 (1.0)
Hyperlipidaemia	10 (1.4)	11 (1.5)
Gout	9 (1.2)	7 (1.0)
Anorexia	7 (1.0)	8 (1.1)

**Table 4. Adverse Events Occurring in  $\geq 1\%$  of Men with Bone Loss Associated with ADT for Nonmetastatic Prostate Cancer**

<b>SYSTEM ORGAN CLASS Preferred Term</b>	<b>PROLIA (N = 731) n (%)</b>	<b>Placebo (N = 725) n (%)</b>
<b>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</b>		
Arthralgia	92 (12.6)	80 (11.0)
Back pain	81 (11.1)	74 (10.2)
Pain in extremity	66 (9.0)	51 (7.0)
Musculoskeletal pain	41 (5.6)	26 (3.6)
Osteoarthritis	31 (4.2)	23 (3.2)
Muscle spasms	18 (2.5)	17 (2.3)
Muscular weakness	15 (2.1)	13 (1.8)
Spinal osteoarthritis	14 (1.9)	5 (0.7)
Bone pain	13 (1.8)	18 (2.5)
Joint swelling	13 (1.8)	9 (1.2)
Myalgia	13 (1.8)	10 (1.4)
Arthritis	12 (1.6)	18 (2.5)
Intervertebral disc degeneration	12 (1.6)	16 (2.2)
Neck pain	12 (1.6)	11 (1.5)
Flank pain	8 (1.1)	2 (0.3)
Musculoskeletal chest pain	4 (0.5)	11 (1.5)
Musculoskeletal stiffness	3 (0.4)	8 (1.1)
<b>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)</b>		
Metastases to bone	34 (4.7)	25 (3.4)
Basal cell carcinoma	13 (1.8)	7 (1.0)
<b>NERVOUS SYSTEM DISORDERS</b>		
Dizziness	41 (5.6)	31 (4.3)
Headache	22 (3.0)	27 (3.7)
Hypoaesthesia	16 (2.2)	9 (1.2)
Syncope	14 (1.9)	10 (1.4)
Cerebrovascular accident	13 (1.8)	14 (1.9)
Transient ischaemic attack	11 (1.5)	8 (1.1)
Sciatica	10 (1.4)	11 (1.5)
Dementia	8 (1.1)	6 (0.8)
Amnesia	7 (1.0)	8 (1.1)
<b>PSYCHIATRIC DISORDERS</b>		
Depression	35 (4.8)	28 (3.9)
Insomnia	23 (3.1)	16 (2.2)
Anxiety	11 (1.5)	11 (1.5)
Confusional state	9 (1.2)	1 (0.1)

**Table 4. Adverse Events Occurring in  $\geq 1\%$  of Men with Bone Loss Associated with ADT for Nonmetastatic Prostate Cancer**

<b>SYSTEM ORGAN CLASS Preferred Term</b>	<b>PROLIA (N = 731) n (%)</b>	<b>Placebo (N = 725) n (%)</b>
<b>RENAL AND URINARY DISORDERS</b>		
Haematuria	23 (3.1)	25 (3.4)
Urinary retention	23 (3.1)	11 (1.5)
Dysuria	17 (2.3)	14 (1.9)
Nocturia	17 (2.3)	17 (2.3)
Pollakiuria	16 (2.2)	24 (3.3)
Urine flow decreased	11 (1.5)	4 (0.6)
Urinary incontinence	9 (1.2)	8 (1.1)
Micturition urgency	8 (1.1)	11 (1.5)
Renal failure	8 (1.1)	9 (1.2)
Nephrolithiasis	5 (0.7)	10 (1.4)
<b>REPRODUCTIVE SYSTEM AND BREAST DISORDERS</b>		
Gynaecomastia	13 (1.8)	16 (2.2)
Erectile dysfunction	8 (1.1)	1 (0.1)
<b>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</b>		
Cough	33 (4.5)	27 (3.7)
Dyspnoea	32 (4.4)	31 (4.3)
Chronic obstructive pulmonary disease	13 (1.8)	10 (1.4)
Pleural effusion	13 (1.8)	7 (1.0)
<b>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</b>		
Rash	16 (2.2)	17 (2.3)
Pruritus	6 (0.8)	11 (1.5)
<b>VASCULAR DISORDERS</b>		
Hypertension	57 (7.8)	51 (7.0)
Hot flush	38 (5.2)	32 (4.4)
Aortic calcification	10 (1.4)	9 (1.2)
Hypotension	10 (1.4)	7 (1.0)
Aortic aneurysm	6 (0.8)	9 (1.2)

N = Number of subjects who received  $\geq 1$  dose of investigational product

n = Number of subjects reporting  $\geq 1$  event

Includes only treatment-emergent adverse events

### **New Malignancies**

Over the entire study period (double-blind and safety follow-up), the subject incidence of new primary malignancy adverse events was 7.0% in PROLIA-treated patients and 5.5% in placebo-treated patients. In the open-label extension period, the subject incidence of new primary malignancy adverse events was 5.5% in the PROLIA/PROLIA group and 2.2% in the placebo/PROLIA group.

### **Osteonecrosis of the Jaw**

Osteonecrosis of the jaw (ONJ) has been reported in patients treated with denosumab or bisphosphonates, another class of anti-resorptive agents (see **WARNINGS AND PRECAUTIONS, Osteonecrosis of the Jaw**).

### **Hypocalcemia**

PROLIA administration was associated with decreases in serum calcium. Hypocalcemia was reported in 1 (0.1%) subject in the PROLIA group and 0 subjects in the placebo group.

### **Hypersensitivity**

Adverse events potentially associated with hypersensitivity were reported in 37 (5.1%) subjects in the PROLIA group and 35 (4.8%) subjects in the placebo group.

### **Infections**

Infections were reported in 257 (35.2%) subjects in the PROLIA group and 226 (31.2%) subjects in the placebo group. Serious adverse events of infection were reported for 43 (5.9%) PROLIA subjects and 33 (4.6%) placebo subjects. A difference in the subject incidence of serious adverse events of diverticulitis was observed (5 [0.7%] PROLIA vs. 0 placebo).

### **Cataracts**

In PROLIA-treated men with nonmetastatic prostate cancer receiving ADT, a greater incidence of cataracts was observed (34 [4.7%] PROLIA, 9 [1.2%] placebo). During the 24-month safety follow-up period, cataracts were reported in 1.0% of subjects in the prior PROLIA group and 1.8% of subjects in the prior placebo group.

### **Atypical Femoral Fracture**

Atypical femoral fractures have been reported in patients receiving PROLIA (see **WARNINGS AND PRECAUTIONS, Atypical Femoral Fractures**).

### **Treatment to Increase Bone Mass in Women Receiving Adjuvant AI Therapy for Nonmetastatic Breast Cancer Who Have Low Bone Mass and are at High Risk for Fracture**

The safety of PROLIA in the treatment of bone loss in women with breast cancer receiving adjuvant AI therapy was assessed in a 2 year, randomized, double-blind, placebo-controlled, multinational study.



During the double-blind phase, a total of 252 postmenopausal women aged 35 to 84 years were enrolled. A total of 120 women were exposed to placebo and 129 women were exposed to PROLIA, administered once every 6 months as a single 60 mg subcutaneous dose. All women were instructed to take 1000 mg of calcium and at least 400 IU of vitamin D supplementation per day.

Adverse events reported in  $\geq 5\%$  of PROLIA-treated patients receiving adjuvant AI therapy for breast cancer, and more frequently than in the placebo-treated patients were (PROLIA vs. placebo): pain in extremity (19 [14.7%] vs. 14 [11.7%]), back pain (18 [14.0%] vs. 15 [12.5%]), constipation (15 [11.6%] vs. 11 [9.2%]), cough (13 [10.1%] vs. 5 [4.2%]), headache (11 [8.5%] vs. 9 [7.5%]), myalgia (11 [8.5%] vs. 5 [4.2%]), shoulder pain (11 [8.5%] vs. 4 [3.3%]), rash (10 [7.8%] vs. 6 [5.0%]), upper respiratory tract infection (10 [7.8%] vs. 6 [5.0%]), sinusitis (9 [7.0%] vs. 4 [3.3%]), vulvovaginal dryness (9 [7.0%] vs. 3 [2.5%]), anxiety (8 [6.2%] vs. 6 [5.0%]), oedema peripheral (8 [6.2%] vs. 5 [4.2%]), vomiting (8 [6.2%] vs. 6 [5.0%]), dyspnoea (7 [5.4%] vs. 5 [4.2%]), hypoaesthesia (7 [5.4%] vs. 4 [3.3%]), muscle spasms (7 [5.4%] vs. 6 [5.0%]), musculoskeletal chest pain (7 [5.4%] vs. 6 [5.0%]), and urinary tract infection (7 [5.4%] vs. 5 [4.2%]).

New primary malignancy was reported in 0 patients in the PROLIA group and 1 patient in the placebo group (0.8%) (gastric cancer). The incidence of malignant disease progression (breast cancer) was 3% in both treatment groups (4 subjects in the PROLIA group, 4 subjects in the placebo group), with 1 death in each treatment group being attributable to underlying breast cancer. During the safety follow-up phase, new primary malignancies were reported in 1 patient in the prior PROLIA group (adenocarcinoma of the pancreas) and 1 patient in the prior placebo group (multiple myeloma). Three patients (3.1%) in the prior PROLIA group and 4 patients (4.4%) in the prior placebo group had an adverse event of metastasis.

A higher number of positively adjudicated fracture events was observed in patients treated with PROLIA after discontinuation of treatment, compared with the 24 months treatment phase (off-treatment vs. on-treatment): osteoporotic vertebral fracture: 2 (2.1%) vs. 0; non-vertebral: 11 (11.5%) vs. 8 (6.0%). In patients treated with placebo, no increase was noted: osteoporotic vertebral fracture: 0 vs. 0; non-vertebral: 5 (5.6%) vs. 8 (6.0%).

The incidence of SAEs was 14.7% (n = 19) in the PROLIA group and 9.2% (n = 11) in the placebo group. The 3 most common serious adverse events were osteoarthritis (2 [1.6%] PROLIA, 0 [0.0%] placebo), myocardial infarction (1 [0.8%] PROLIA, 0 [0.0%] placebo), and transient ischemic attack (1 [0.8%] PROLIA, 1 [0.8%] placebo). Deaths occurred in 1 subject (0.8%) in the PROLIA group and 1 subject (0.8%) in the placebo group.

The percentage of patients who withdrew from the study due to adverse events was 1 (0.8%) and 5 (4.2%) for the PROLIA and placebo groups, respectively.

Adverse events reported in  $\geq 1\%$  of PROLIA-treated or placebo-treated patients are shown in Table 5.

**Table 5. Adverse Events Occurring in  $\geq 1\%$  of Women with Bone Loss Associated with Adjuvant AI Therapy for Breast Cancer**

<b>SYSTEM ORGAN CLASS Preferred Term</b>	<b>PROLIA (N = 129) n (%)</b>	<b>Placebo (N = 120) n (%)</b>
<b>BLOOD AND LYMPHATIC SYSTEM DISORDERS</b>		
Anaemia	2 (1.6)	3 (2.5)
<b>CARDIAC DISORDERS</b>		
Palpitations	2 (1.6)	2 (1.7)
Atrial fibrillation	0 (0.0)	2 (1.7)
Cardiac failure congestive	0 (0.0)	2 (1.7)
<b>EAR AND LABYRINTH DISORDERS</b>		
Tinnitus	0 (0.0)	2 (1.7)
<b>ENDOCRINE DISORDERS</b>		
Hypothyroidism	3 (2.3)	2 (1.7)
<b>EYE DISORDERS</b>		
Visual disturbance	3 (2.3)	0 (0.0)
Dry eye	2 (1.6)	0 (0.0)
Eye haemorrhage	0 (0.0)	2 (1.7)
<b>GASTROINTESTINAL DISORDERS</b>		
Constipation	15 (11.6)	11 (9.2)
Nausea	10 (7.8)	11 (9.2)
Vomiting	8 (6.2)	6 (5.0)
Abdominal pain	6 (4.7)	4 (3.3)
Diarrhoea	5 (3.9)	9 (7.5)
Dyspepsia	4 (3.1)	5 (4.2)
Dry mouth	3 (2.3)	2 (1.7)
Haemorrhoids	3 (2.3)	2 (1.7)
Abdominal discomfort	2 (1.6)	2 (1.7)
Abdominal pain upper	2 (1.6)	1 (0.8)
Gastrooesophageal reflux disease	2 (1.6)	8 (6.7)
Stomatitis	2 (1.6)	1 (0.8)
Abdominal distension	0 (0.0)	2 (1.7)
Hiatus hernia	0 (0.0)	2 (1.7)
Irritable bowel syndrome	0 (0.0)	2 (1.7)
<b>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</b>		
Fatigue	17 (13.2)	17 (14.2)
Oedema peripheral	8 (6.2)	5 (4.2)
Chest pain	6 (4.7)	2 (1.7)

**Table 5. Adverse Events Occurring in  $\geq 1\%$  of Women with Bone Loss Associated with Adjuvant AI Therapy for Breast Cancer**

<b>SYSTEM ORGAN CLASS</b>	<b>PROLIA (N = 129)</b>	<b>Placebo (N = 120)</b>
<b>Preferred Term</b>	<b>n (%)</b>	<b>n (%)</b>
Pain	5 (3.9)	3 (2.5)
Pyrexia	4 (3.1)	1 (0.8)
Non-cardiac chest pain	3 (2.3)	1 (0.8)
Asthenia	2 (1.6)	1 (0.8)
Axillary pain	2 (1.6)	1 (0.8)
Injection site pain	2 (1.6)	2 (1.7)
Localised oedema	2 (1.6)	0 (0.0)
Pelvic mass	2 (1.6)	0 (0.0)
Malaise	1 (0.8)	3 (2.5)
<b>HEPATOBIILIARY DISORDERS</b>		
Cholelithiasis	1 (0.8)	4 (3.3)
<b>IMMUNE SYSTEM DISORDERS</b>		
Hypersensitivity	3 (2.3)	3 (2.5)
<b>INFECTIONS AND INFESTATIONS</b>		
Upper respiratory tract infection	10 (7.8)	6 (5.0)
Sinusitis	9 (7.0)	4 (3.3)
Urinary tract infection	7 (5.4)	5 (4.2)
Bronchitis	5 (3.9)	7 (5.8)
Herpes zoster	4 (3.1)	2 (1.7)
Influenza	4 (3.1)	5 (4.2)
Nasopharyngitis	4 (3.1)	4 (3.3)
Cellulitis	3 (2.3)	1 (0.8)
Herpes simplex	3 (2.3)	0 (0.0)
Hordeolum	3 (2.3)	0 (0.0)
Pneumonia	2 (1.6)	1 (0.8)
Tinea infection	2 (1.6)	0 (0.0)
Vaginal infection	0 (0.0)	2 (1.7)
<b>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</b>		
Procedural pain	4 (3.1)	3 (2.5)
Contusion	3 (2.3)	5 (4.2)
Foot fracture	3 (2.3)	2 (1.7)
Excoriation	2 (1.6)	0 (0.0)
Fibula fracture	2 (1.6)	0 (0.0)
Joint sprain	2 (1.6)	3 (2.5)
Post-traumatic pain	2 (1.6)	0 (0.0)
Rib fracture	2 (1.6)	1 (0.8)
Fall	1 (0.8)	4 (3.3)

**Table 5. Adverse Events Occurring in  $\geq 1\%$  of Women with Bone Loss Associated with Adjuvant AI Therapy for Breast Cancer**

<b>SYSTEM ORGAN CLASS</b>	<b>PROLIA (N = 129)</b>	<b>Placebo (N = 120)</b>
<b>Preferred Term</b>	<b>n (%)</b>	<b>n (%)</b>
Meniscus lesion	1 (0.8)	2 (1.7)
Radius fracture	1 (0.8)	2 (1.7)
Incision site complication	0 (0.0)	3 (2.5)
<b>INVESTIGATIONS</b>		
Weight decreased	5 (3.9)	2 (1.7)
Blood cholesterol increased	4 (3.1)	1 (0.8)
Blood pressure increased	3 (2.3)	1 (0.8)
Weight increased	1 (0.8)	3 (2.5)
<b>METABOLISM AND NUTRITION DISORDERS</b>		
Decreased appetite	4 (3.1)	3 (2.5)
Hypercholesterolaemia	3 (2.3)	1 (0.8)
Hypokalaemia	3 (2.3)	2 (1.7)
Anorexia	2 (1.6)	1 (0.8)
<b>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</b>		
Arthralgia	31 (24.0)	30 (25.0)
Pain in extremity	19 (14.7)	14 (11.7)
Back pain	18 (14.0)	15 (12.5)
Myalgia	11 (8.5)	5 (4.2)
Shoulder pain	11 (8.5)	4 (3.3)
Muscle spasms	7 (5.4)	6 (5.0)
Musculoskeletal chest pain	7 (5.4)	6 (5.0)
Osteoarthritis	6 (4.7)	3 (2.5)
Arthritis	5 (3.9)	6 (5.0)
Bone pain	5 (3.9)	8 (6.7)
Exostosis	4 (3.1)	1 (0.8)
Musculoskeletal discomfort	4 (3.1)	1 (0.8)
Intervertebral disc protrusion	3 (2.3)	2 (1.7)
Joint swelling	3 (2.3)	3 (2.5)
Osteopenia	3 (2.3)	0 (0.0)
Bunion	2 (1.6)	0 (0.0)
Joint range of motion decreased	2 (1.6)	1 (0.8)
Muscular weakness	2 (1.6)	0 (0.0)
Neck pain	2 (1.6)	1 (0.8)
Tendonitis	2 (1.6)	3 (2.5)
Musculoskeletal pain	0 (0.0)	2 (1.7)
Musculoskeletal stiffness	0 (0.0)	2 (1.7)

**Table 5. Adverse Events Occurring in  $\geq 1\%$  of Women with Bone Loss Associated with Adjuvant AI Therapy for Breast Cancer**

<b>SYSTEM ORGAN CLASS Preferred Term</b>	<b>PROLIA (N = 129) n (%)</b>	<b>Placebo (N = 120) n (%)</b>
<b>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)</b>		
Benign breast neoplasm	5 (3.9)	1 (0.8)
Basal cell carcinoma	2 (1.6)	3 (2.5)
Breast cancer in situ	2 (1.6)	0 (0.0)
Metastases to bone	2 (1.6)	3 (2.5)
Seborrhoeic keratosis	2 (1.6)	0 (0.0)
Uterine leiomyoma	2 (1.6)	0 (0.0)
<b>NERVOUS SYSTEM DISORDERS</b>		
Headache	11 (8.5)	9 (7.5)
Hypoaesthesia	7 (5.4)	4 (3.3)
Dizziness	5 (3.9)	4 (3.3)
Neuropathy	3 (2.3)	0 (0.0)
Tremor	3 (2.3)	0 (0.0)
Amnesia	2 (1.6)	0 (0.0)
Memory impairment	2 (1.6)	0 (0.0)
Neuropathy peripheral	2 (1.6)	1 (0.8)
Paraesthesia	2 (1.6)	2 (1.7)
Neuralgia	0 (0.0)	2 (1.7)
<b>PSYCHIATRIC DISORDERS</b>		
Insomnia	12 (9.3)	14 (11.7)
Anxiety	8 (6.2)	6 (5.0)
Depression	7 (5.4)	11 (9.2)
Mood swings	3 (2.3)	0 (0.0)
<b>RENAL AND URINARY DISORDERS</b>		
Pollakiuria	5 (3.9)	1 (0.8)
Incontinence	3 (2.3)	0 (0.0)
Nocturia	2 (1.6)	1 (0.8)
<b>REPRODUCTIVE SYSTEM AND BREAST DISORDERS</b>		
Vulvovaginal dryness	9 (7.0)	3 (2.5)
Breast cyst	3 (2.3)	0 (0.0)
Breast pain	3 (2.3)	6 (5.0)
Vaginal haemorrhage	3 (2.3)	1 (0.8)
Breast tenderness	2 (1.6)	1 (0.8)
Breast induration	0 (0.0)	2 (1.7)

**Table 5. Adverse Events Occurring in  $\geq 1\%$  of Women with Bone Loss Associated with Adjuvant AI Therapy for Breast Cancer**

<b>SYSTEM ORGAN CLASS</b>	<b>PROLIA</b>	<b>Placebo</b>
<b>Preferred Term</b>	<b>(N = 129)</b>	<b>(N = 120)</b>
	<b>n (%)</b>	<b>n (%)</b>
<b>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</b>		
Cough	13 (10.1)	5 (4.2)
Dyspnoea	7 (5.4)	5 (4.2)
Pharyngolaryngeal pain	5 (3.9)	1 (0.8)
Nasal congestion	3 (2.3)	0 (0.0)
Respiratory tract congestion	2 (1.6)	1 (0.8)
Rhinorrhoea	2 (1.6)	0 (0.0)
Rhinitis allergic	1 (0.8)	2 (1.7)
Sinus congestion	1 (0.8)	2 (1.7)
Chronic obstructive pulmonary disease	0 (0.0)	2 (1.7)
Epistaxis	0 (0.0)	2 (1.7)
Pneumonitis	0 (0.0)	2 (1.7)
<b>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</b>		
Rash	10 (7.8)	6 (5.0)
Alopecia	5 (3.9)	2 (1.7)
Night sweats	3 (2.3)	0 (0.0)
Dry skin	2 (1.6)	1 (0.8)
Erythema	2 (1.6)	2 (1.7)
Skin lesion	2 (1.6)	1 (0.8)
Dermatitis	1 (0.8)	2 (1.7)
Hyperhidrosis	1 (0.8)	2 (1.7)
Dermatitis contact	0 (0.0)	2 (1.7)
Nail disorder	0 (0.0)	3 (2.5)
<b>VASCULAR DISORDERS</b>		
Hot flush	7 (5.4)	8 (6.7)
Lymphoedema	4 (3.1)	4 (3.3)
Hypertension	2 (1.6)	7 (5.8)

N = Number of subjects who received  $\geq 1$  dose of investigational product

n = Number of subjects reporting  $\geq 1$  event

Includes only treatment-emergent adverse events

## **Postmarket Adverse Drug Reactions**

### **Hypersensitivity Reactions**

Hypersensitivity reactions including rash, urticaria, facial swelling, erythema, and anaphylactic reactions have been reported in patients receiving PROLIA.

### **Musculoskeletal Pain**

Musculoskeletal pain, including severe cases, has been reported in patients receiving PROLIA.

### **Severe Hypocalcemia**

Symptoms of hypocalcemia in denosumab clinical studies include parathesias or muscle stiffness, twitching, spasms and muscle cramps. In the postmarket setting severe symptomatic hypocalcemia has been reported in patients at increased risk of hypocalcemia receiving PROLIA with most cases occurring in the first few weeks of initiating therapy. Symptoms of severe hypocalcemia may include QT interval prolongation, tetany and convulsions and altered mental status. Healthcare Professionals should follow standard medical care guidelines for the treatment of signs and symptoms associated with severe hypocalcemia. See **WARNINGS AND PRECAUTIONS, Hypocalcemia** for further information on monitoring hypocalcemia.

### **Osteonecrosis of the Jaw (ONJ)**

Osteonecrosis of the jaw has been reported in patients receiving PROLIA.

## **DRUG INTERACTIONS**

### **Overview**

In subjects with postmenopausal osteoporosis, PROLIA (60 mg SC) did not affect the pharmacokinetics of midazolam, which is metabolized by cytochrome P450 3A4 (CYP3A4), indicating that PROLIA is not expected to affect the pharmacokinetics of drugs metabolized by this enzyme in this population (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics).

### **Drug-Drug Interactions**

Interactions with other drugs have not been established.

The pharmacokinetics and pharmacodynamics of PROLIA were similar in postmenopausal women with osteoporosis transitioning from alendronate therapy compared to those who had not received prior alendronate therapy.

### **Drug-Food Interactions**

Interactions with food have not been established.

### **Drug-Herb Interactions**

Interactions with herbal products have not been established.

### **Drug-Laboratory Interactions**

Interactions with laboratory tests have not been established.

## **DOSAGE AND ADMINISTRATION**

### **Dosing Considerations**

PROLIA is intended for use under the guidance and supervision of physicians who have fully familiarized themselves with the efficacy/safety profile of PROLIA. After an initial training in proper subcutaneous injection technique, patients may self-inject PROLIA if a physician determines that is appropriate and with medical follow-up as necessary. Patients should be informed that serious hypersensitivity reactions including anaphylaxis have been reported with PROLIA injections.

Patients must be adequately supplemented with calcium and vitamin D at the recommended doses<sup>a</sup>.

PROLIA is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, PROLIA reduces the incidence of vertebral, nonvertebral and hip fractures.

PROLIA is also indicated as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. The high risk for fracture is defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

PROLIA is also indicated as a treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT), who are at high risk for fracture.

PROLIA is also indicated as a treatment to increase bone mass in women with nonmetastatic breast cancer receiving adjuvant aromatase inhibitor (AI) therapy, who have low bone mass and are at high risk for fracture.

### **Recommended Dose**

The recommended dose of PROLIA (denosumab) is a single SC injection of 60 mg, once every 6 months.

### **Administration**

Administration of PROLIA should be performed by an individual who has been adequately trained in injection techniques.

The needle cap on the PROLIA single use prefilled syringe contains dry natural rubber (a derivative of latex) that may cause allergic reactions in individuals sensitive to latex.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. PROLIA is a clear, colourless to slightly yellow solution that may contain trace amounts of translucent to white proteinaceous particles. Do not use if the solution is cloudy.

---

<sup>a</sup>2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary



Prior to administration, PROLIA may be allowed to reach room temperature (up to 25°C) in the original container.

Administer PROLIA via SC injection in the upper arm, the upper thigh, or the abdomen.

## **OVERDOSAGE**

For management of a suspected drug overdose, contact your regional Poison Control Centre.

There is no experience with overdose with PROLIA.

## **ACTION AND CLINICAL PHARMACOLOGY**

### **Mechanism of Action**

PROLIA is a RANK ligand (RANKL) inhibitor. RANKL exists as a transmembrane or soluble protein. RANK ligand is essential for the formation, function and survival of osteoclasts, the sole cell type responsible for bone resorption. Osteoclasts play an important role in bone loss associated with osteoporosis and hormone ablation. Denosumab targets and binds with high affinity and specificity to RANKL, preventing RANKL from activating its only receptor, RANK, on the surface of osteoclasts and their precursors, independent of bone surface. Prevention of RANKL-RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone throughout the skeleton.

### **Pharmacodynamics**

In clinical studies, treatment with 60 mg of PROLIA resulted in rapid reduction in the bone resorption marker serum type 1 C-telopeptide (CTX) within 6 hours of SC administration by approximately 70%, with reductions of approximately 85% occurring by 3 days. CTX levels were below the limit of assay quantitation (0.049 ng/mL) in 39 to 68% of subjects 1 to 3 months after dosing of PROLIA. CTX reductions were maintained over the 6-month dosing interval. At the end of each dosing interval, CTX reductions were partially attenuated from maximal reduction of  $\geq 87\%$  to  $\geq 45\%$  (range 45% to 80%), as serum denosumab levels diminished, reflecting the reversibility of the effects of PROLIA on bone remodelling. These effects were maintained with continued treatment. Consistent with the physiological coupling of bone formation and resorption in skeletal remodeling, subsequent reductions in bone formation markers were observed beginning 1 month after the first dose of PROLIA.


Bone turnover markers (bone resorption and formation markers) generally reached pre-treatment levels within 9 months after the last 60 mg SC dose. Upon re-initiation, the degree of inhibition of CTX by PROLIA was similar to that observed in patients initiating PROLIA treatment.

In a clinical study of postmenopausal women with low bone mass (N = 504) who were previously treated with alendronate for a median duration of 3 years, those transitioning to receive PROLIA experienced additional reductions in serum CTX, compared with women who remained on alendronate. In this study, the changes in serum calcium were similar between the 2 groups.

## Pharmacokinetics

In dose ranging studies, denosumab exhibited nonlinear, dose-dependent pharmacokinetics for doses between 0.01 mg/kg to 3.0 mg/kg inclusive. Clearance or apparent clearance (mL/hr/kg) was higher at lower doses and had a linear inverse relationship with dose on a log-log plot. Exposures (SC dosing) based on area under the serum denosumab concentration-time curve (AUC) increased greater than dose-proportionally from 0.01 to 1 mg/kg (700-fold for the 100-fold increase in dose), but approximately dose-proportionally from 1 to 3 mg/kg (3.9-fold for the 3-fold increase in dose).

**Figure 1. Individual Serum Denosumab Concentration-Time Profiles Following Single Dose SC Administration at 1.0 mg/kg to Healthy Postmenopausal Women**



**Table 6. Mean (SD) Denosumab Pharmacokinetic Parameters Following Single Dose SC Administration of 1.0 mg/kg Denosumab to Healthy Postmenopausal Women (N = 6)**

$T_{max}$ (days)	$C_{max}$ ( $\mu\text{g/mL}$ )	$AUC_{0-inf}$ ( $\mu\text{g} \times \text{day/mL}$ )	$CL/F$ (mL/hr)	MRT (days)	$t_{1/2}$ (days)	$t_{1/2,z}$ (days)
17.5 (7 - 42)	8.99 (3.34)	538 (224)	6.61 (2.93)	44.2 (6.96)	30.2 (7.04)	8.00 (0.975)

SD = standard deviation;  $C_{max}$  = Maximum observed concentration;  $T_{max}$  = time of  $C_{max}$  (range reported instead of SD);  $AUC_{0-inf}$  = Area under the serum concentration-time curve from pre-dose to infinity;  $CL/F$  = apparent clearance; MRT = mean residence time;  $t_{1/2}$  = half-life following  $C_{max}$ ;  $t_{1/2,z}$  = terminal-phase half-life

**Table 7. Mean (SD) Denosumab Pharmacokinetic Parameters Following SC Administration of 60 mg Denosumab Every 6 Months to Postmenopausal Women with Low BMD (n = 32-46)\***

Dose	T <sub>max</sub> (days)	C <sub>max</sub> (µg/mL)	AUC <sub>0-tau</sub> (µg x day/mL)	CL/F (mL/hr)	MRT (days)	t <sub>1/2</sub> (days)	C <sub>min</sub> (µg/mL)
1 <sup>st</sup>	26 (2.9 - 32)	7.93 (2.95)	503 (239)	6.71 (5.00)	44.2 (9.48)	25.4 (8.47)	0.137 (0.334)
2 <sup>nd</sup>	29 (1.9 - 42)	6.94 (3.18)	448 (239)	7.50 (5.04)	45.0 (9.99)	27.1 (8.99)	0.132 (0.334)

SD = standard deviation; C<sub>max</sub> = Maximum observed concentration; T<sub>max</sub> = time of C<sub>max</sub> (range reported instead of SD); AUC<sub>0-tau</sub> = area under the serum denosumab concentration-time curve over the dosing interval; CL/F = apparent clearance; MRT = mean residence time; t<sub>1/2</sub> = half-life following C<sub>max</sub>; C<sub>min</sub> = trough serum denosumab concentration  
 \*1<sup>st</sup> dose: n = 46 for T<sub>max</sub>, C<sub>max</sub>, AUC<sub>0-tau</sub>, CL/F, & MRT; n = 32 for t<sub>1/2</sub>; n = 38 for C<sub>min</sub>  
 \*2<sup>nd</sup> dose: n = 44 for T<sub>max</sub>, C<sub>max</sub>, AUC<sub>0-tau</sub>, CL/F, & MRT; n = 33 for t<sub>1/2</sub>; n = 39 for C<sub>min</sub>

Denosumab pharmacokinetic parameters were not affected by the formation of binding antibodies to denosumab.

At the level of the administered dose, the pharmacokinetics of denosumab do not appear to be affected by gender, age (28 to 87 years), race, or disease state.

In a study of 17 postmenopausal women with osteoporosis, midazolam (2 mg oral) was administered two weeks after a single dose of denosumab (60 mg SC), which approximates the median time to maximum denosumab concentration (T<sub>max</sub>) of 10 days (range: 3 to 21 days). Denosumab did not affect the pharmacokinetics of midazolam, which is metabolized by cytochrome P450 3A4 (CYP3A4). This indicates that denosumab is not expected to alter the pharmacokinetics of drugs metabolized by CYP3A4 in postmenopausal women with osteoporosis.

## **Special Populations**

### **Geriatrics**

The pharmacokinetics of denosumab were not affected by age.

### **Pediatrics**

The pharmacokinetics of denosumab in pediatric patients has not been assessed.

### **Race**

The pharmacokinetics of denosumab were not affected by race in post-menopausal women.

### **Hepatic Impairment**

No clinical studies have been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of denosumab.

### **Renal Impairment**

In a study of 55 patients with varying degrees of renal function, including patients on dialysis, the degree of renal impairment had no effect on the pharmacokinetics of denosumab; thus, dose adjustment for renal impairment is not necessary.

## **STORAGE AND STABILITY**

Store PROLIA in a refrigerator at 2°C to 8°C in the original carton. Do not freeze.

If removed from the refrigerator, PROLIA should be kept at controlled room temperature (up to 25°C) in the original carton and must be used within 30 days.

Protect PROLIA from light and do not expose to temperatures above 25°C.

Avoid vigorous shaking of PROLIA.

Do not use PROLIA beyond the expiry date stamped on the label.

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

PROLIA is a sterile, preservative-free, clear, colourless to slightly yellow solution formulated at pH 5.2.

PROLIA is supplied in a single use prefilled syringe with a safety guard. The needle cap on the single use prefilled syringe contains dry natural rubber (a derivative of latex).

Each 1.0 mL single use prefilled syringe of PROLIA contains 60 mg denosumab, 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, water for injection (USP), and sodium hydroxide to a pH of 5.2.

PROLIA is supplied in a dispensing pack containing one prefilled syringe.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance

Proper name:	denosumab
Molecular mass:	147 kDa (approximate)
Structural formula:	Denosumab is a fully human IgG2 monoclonal antibody heterotetramer consisting of 2 heavy chains of the gamma 2 subclass (447 amino acids per chain) and 2 light chains of the kappa subclass (215 amino acids per chain).
Physicochemical Properties:	Prolia® (denosumab) is a clear, colourless to slightly yellow solution. The solution may contain trace amounts of translucent to white proteinaceous particles.

### CLINICAL TRIALS

#### Treatment of Osteoporosis in Postmenopausal Women

##### **Study Demographics and Design [Study 1 (FREEDOM)]**

In postmenopausal women with osteoporosis, the safety and efficacy of PROLIA (denosumab) were assessed in a randomized double-blind controlled study.

Study #	Trial Design	Dosage , route of administration and duration	Study patients (n)	Mean age (range) (yrs)
Study 1 (FREEDOM)	Phase 3, randomized, double-blind, placebo-controlled	PROLIA 60 mg or placebo SC injection every 6 months for 3 years	7808 patients with osteoporosis (PROLIA: 3902 Placebo: 3906)	72 (60, 91)

The efficacy and safety of PROLIA administered once every 6 months for 3 years were investigated in postmenopausal women (7,808 women aged 60-91 years, of which 23.6% had prevalent vertebral fractures) with baseline bone mineral density (BMD) T-scores at the lumbar spine or total hip between -2.5 and -4.0 and a mean absolute 10-year fracture probability of 18.60% (deciles: 7.9-32.4%) for major osteoporotic fracture and 7.22% (deciles: 1.4-14.9%) for hip fracture. Women with other diseases or on therapies that may affect bone (such as rheumatoid arthritis, osteogenesis imperfecta, and Paget's disease) were excluded from this study. Women were randomized to receive SC injections of either placebo (n = 3906) or PROLIA 60 mg (n = 3902) once every 6 months. Women received calcium (at least 1,000 mg) and vitamin D (at least 400 IU) supplementation daily. The primary efficacy variable was the incidence of new vertebral fractures over 3 years. Secondary efficacy variables included the incidence of non-vertebral fracture and hip fracture, assessed over 3 years. The study was

powered to detect a 45% reduction in the incidence of new vertebral fractures, a 40% decrease in the risk of non-vertebral fractures and a 40% decrease in the risk of hip fractures.

## Effects on Fracture Incidence

### New Vertebral Fractures

PROLIA, when taken with calcium and vitamin D and compared with calcium and vitamin D alone, significantly reduced the incidence of new vertebral fractures over 36 months from 7.2% in the placebo group to 2.3% in the PROLIA group ( $p < 0.0001$ ). The absolute reduction in risk of vertebral fractures was 4.8% and the relative reduction was 68% (Table 8). The number needed to treat (NNT) over the three years to prevent 1 new vertebral fracture was 20.7 (95% CI: 17.3, 25.8).

**Table 8. The Effect of PROLIA on Vertebral Fracture Incidence over 3 Years**

	Proportion of Women with Fracture (%)		Absolute Risk Reduction (%) (95% CI)	Relative Risk Reduction (%) (95% CI)
	Placebo N = 3691 (%)	PROLIA N = 3702 (%)		
0 - 1 Year	2.2	0.9	1.4 (0.8, 1.9)	61 (42, 74)*
0 - 2 Years	5.0	1.4	3.5 (2.7, 4.3)	71 (61, 79)*
0 - 3 Years	7.2	2.3	4.8 (3.9, 5.8)	68 (59, 74)*

\* $p < 0.0001$

N = Number of women in the primary efficacy analysis set

In the long-term, open-label extension of Study 1, among 2343 women who received PROLIA in Study 1 and continued on therapy (years 4 through 10 of PROLIA treatment), 1343 (57.3%) completed 10 years. PROLIA treatment maintained a low incidence of new vertebral fractures in years 4 through 10 (149 [7.0%] women had at least one new vertebral fracture and 43 [2.4%] women had a clinical vertebral fracture by year 7 of the extension study). The yearly incremental incidences of new vertebral fractures remained low (see Table 9).

Among 2207 women who crossed over to PROLIA from placebo in Study 1, 1283 (58.1%) completed 10 years, and the incidence of new vertebral fractures was low (145 [7.3%] had at least one new vertebral fracture and 33 [1.9%] had a clinical vertebral fracture by year 7 of the extension study). The yearly incremental incidences of new vertebral fractures remained low (see Table 9).

**Table 9. The Effect of PROLIA on the Yearly Incidence of New Vertebral Fracture in the Extension Study**

Long-term PROLIA Group <sup>1</sup>		Cross-over PROLIA Group <sup>2</sup>	
Exposure to PROLIA	Proportion of Women with New Vertebral Fractures (%) <sup>3</sup>	Exposure to PROLIA	Proportion of Women with New Vertebral Fractures (%) <sup>3</sup>
Year 4	1.5 <sup>4</sup> (N = 2116)	Year 1	0.9 <sup>4</sup> (N = 1991)
Year 5		Year 2	
Year 6	1.2 (N = 1809)	Year 3	1.5 (N = 1695)
Year 7	1.4 <sup>4</sup> (N = 1585)	Year 4	1.9 <sup>4</sup> (N = 1508)
Year 8		Year 5	
Year 9	1.3 <sup>4</sup> (N = 1323)	Year 6	1.6 <sup>4</sup> (N = 1267)
Year 10		Year 7	

<sup>1</sup> Long-term PROLIA group: women who received PROLIA in Study 1 and continued on therapy in the extension

<sup>2</sup> Cross-over PROLIA group: women who received placebo in Study 1 and transitioned to PROLIA in the extension

<sup>3</sup> Based on crude incidence

<sup>4</sup> Annualized yearly subject incidence

### Hip Fractures

The incidence of hip fracture was 1.2% for placebo-treated women compared to 0.7% for PROLIA-treated women. The observed absolute reduction in the risk of hip fracture at 3 years was 0.3%, with a 95% CI across the zero (-0.1%, 0.7%), and the relative risk reduction was 40% (95% CI: 0.37, 0.97; p = 0.0362).

Among women who received PROLIA for 3 years in Study 1 and continued on therapy in the long-term, open-label extension, PROLIA treatment maintained a low incidence of hip fractures in years 4 through 10 (22 [1.2%] women had at least one hip fracture). The yearly incremental incidences of hip fractures remained low (0.3%, <0.1%, 0.2%, 0.1%, 0.2%, <0.1%, and 0.4% during 4, 5, 6, 7, 8, 9 and 10 years of exposure to PROLIA, respectively).

Women who crossed over to PROLIA from placebo in Study 1, had a low incidence of hip fractures by year 7 of the extension study (26 [1.4%] women had at least one hip fracture). The yearly incremental incidences of hip fractures remained low (0.6%, 0.1%, 0.2%, <0.1%, 0.1%, 0.1% and 0.2% during 1, 2, 3, 4, 5, 6 and 7 years of exposure to PROLIA, respectively).

### Non-vertebral Fractures

The incidence of non-vertebral fracture was 8.0% for placebo-treated women, compared with 6.5% for PROLIA-treated women. The observed absolute reduction in risk of non-vertebral fractures over 3 years was 1.5% (0.3, 2.7) and the relative risk reduction was 20% (95% CI: 5, 33%; p = 0.0106).

The incidences of nonvertebral fractures at other locations were as follows: distal femur (3 [< 0.1%] placebo, 0 [0%] PROLIA), forearm (120 [3.1%] placebo, 103 [2.6%] PROLIA), wrist (107 [2.7%] placebo, 90 [2.3%] PROLIA), humerus (45 [1.2%] placebo, 38 [1.0%] PROLIA), proximal humerus (41 [1.0%] placebo, 30 [0.8%] PROLIA), clavicle/rib (25 [0.6%] placebo, 34

[0.9%] PROLIA), proximal tibia (5 [0.1%] placebo, 3 [ $< 0.1\%$ ] PROLIA), and pelvic (13 [0.3%] placebo, 10 [0.3%] PROLIA).

Among women who received PROLIA for 3 years in Study 1 and continued on therapy in the long-term, open-label extension, PROLIA treatment maintained a low incidence of nonvertebral fractures in years 4 through 10 (172 [9.3%] women had at least one nonvertebral fracture). The yearly incremental incidences of nonvertebral fractures remained low (1.5%, 1.2%, 1.8%, 1.6%, 0.8%, 1.1% and 1.9% during 4, 5, 6, 7, 8, 9 and 10 years of exposure to PROLIA, respectively). The most common sites for nonvertebral fractures during the long-term, open-label extension of Study 1 were wrist (n = 70), rib/clavicle (n = 23), hip (n = 22), and ankle (n = 17) (with n = number of affected women).

Among women who crossed over to PROLIA from placebo in Study 1, 219 (12.3%) women had at least one nonvertebral fracture by year 7 of the extension study. The yearly incremental incidences of nonvertebral fractures remained low (2.5%, 2.0%, 2.6%, 1.2%, 1.8%, 1.5% and 1.7% during 1, 2, 3, 4, 5, 6 and 7 years of exposure to PROLIA, respectively). The most common sites for nonvertebral fractures during the first 7 years in the extension were wrist (n = 91), hip (n = 26), ankle (n = 24), humerus (n = 23) and rib/clavicle (n = 20).

### **Effect on Bone Mineral Density (BMD)**

Treatment with PROLIA significantly increased BMD at all clinical sites measured at 1, 2, and 3 years. PROLIA increased lumbar spine BMD by 8.8%, total hip BMD by 6.4%, femoral neck BMD by 5.2%, and hip trochanter BMD by 8.3% over 3 years (all  $p < 0.0001$ ).

In the long-term, open-label extension of Study 1, in women who received PROLIA in Study 1 and continued on therapy (years 4 through 10 of PROLIA treatment), PROLIA treatment continued to increase BMD from extension baseline at the lumbar spine (10.8%; n = 1264), total hip (3.4%; n = 1232), femoral neck (3.8%; n = 1232) and trochanter (5.1%; n = 1232) in years 4 through 10. Percent increase in BMD from the original Study 1 baseline (ie, after 10 years of treatment) in the long-term group was 21.7% at the lumbar spine, 9.2% at the total hip, 9.0% at the femoral neck and 13.0% at the trochanter (all n = 1251). Annualized changes in BMD in the long-term, open-label extension portion of Study 1 are shown in Table 10.

Among women who crossed over to PROLIA from placebo in Study 1, BMD gains from extension baseline were 16.5% (lumbar spine; n = 1223), 7.4% (total hip; n = 1200), 7.1% (femoral neck; n = 1200), and 10.3% (trochanter; n = 1200) after 7 years of denosumab administration. Annualized changes in BMD in the cross-over, open-label extension portion of Study 1 are shown in Table 10.



**Table 10. Bone Mineral Density Yearly Percent Change by Site in the Extension Study**

Long-term PROLIA Group					Cross-over PROLIA Group				
Exposure to PROLIA	Lumbar Spine % (n)	Total Hip % (n)	Femoral Neck % (n)	Trochanter % (n)	Exposure to PROLIA	Lumbar Spine % (n)	Total Hip % (n)	Femoral Neck % (n)	Trochanter % (n)
Year 4	1.8 (2087)	0.8 (2065)	0.9 (2065)	1.1 (2065)	Year 1	5.4 (1980)	3.1 (1941)	2.3 (1941)	4.1 (1941)
Year 5	1.7 (2017)	0.6 (1998)	0.4 (1998)	0.9 (1998)	Year 2	2.5 (1898)	1.1 (1870)	1.1 (1870)	1.4 (1870)
Year 6	1.5 (1572)	0.5 (1549)	0.5 (1549)	0.8 (1549)	Year 3	1.7 (1468)	0.8 (1439)	0.8 (1439)	1.2 (1439)
Year 7	1.6 <sup>a</sup> (1361)	0.4 <sup>a</sup> (1330)	0.6 <sup>a</sup> (1330)	0.6 <sup>a</sup> (1330)	Year 4	1.8 <sup>a</sup> (1281)	0.7 <sup>a</sup> (1252)	0.8 <sup>a</sup> (1252)	0.9 <sup>a</sup> (1252)
Year 8					Year 5				
Year 9	1.6 <sup>a</sup> (1245)	0.4 <sup>a</sup> (1206)	0.5 <sup>a</sup> (1206)	0.7 <sup>a</sup> (1206)	Year 6	1.8 <sup>a</sup> (1206)	0.6 <sup>a</sup> (1174)	0.7 <sup>a</sup> (1174)	0.9 <sup>a</sup> (1174)
Year 10					Year 7				

<sup>a</sup> Annualized yearly change

n = Number of subjects with observed data at both time points of interest

### Bone Histology and Histomorphometry

A total of 115 transiliac crest bone biopsy specimens were obtained from 92 postmenopausal women with osteoporosis at either month 24 and/or month 36 (53 specimens in PROLIA group, 62 specimens in placebo group). Of the biopsies obtained, 115 (100%) were adequate for qualitative histology and 7 (6%) in the denosumab group were adequate for full quantitative histomorphometry assessment.

Qualitative histology assessments showed normal architecture and quality with no evidence of mineralization defects, woven bone, or marrow fibrosis in patients treated with PROLIA.

Fifty-nine women participated in the bone biopsy sub-study at month 24 (N=41) and/or month 84 (N=22) of the extension study, representing up to 5 and 10 years of treatment with PROLIA, respectively. Bone biopsy results showed bone of normal architecture and quality with no evidence of mineralization defects, woven bone or marrow fibrosis as well as the expected decrease in bone turnover.

The presence of double tetracycline labeling in a biopsy specimen provides an indication of active bone remodeling, while the absence of tetracycline label suggests suppressed bone formation. In subjects treated with PROLIA, 35% had no tetracycline label present at the month 24 biopsy and 38% had no tetracycline label present at the month 36 biopsy, while 100% of placebo-treated patients had double label present at both time points. When compared to placebo, treatment with PROLIA resulted in virtually absent activation frequency and markedly reduced bone formation rates. However, the long-term consequences of this degree of suppression of bone remodeling are unknown.

## **Treatment to Increase Bone Mass in Men with Osteoporosis at High Risk for Fracture**

### **Study Demographics and Design [Study 5 (ADAMO)]**

In men with osteoporosis, the efficacy and safety of PROLIA were assessed in a randomized, double-blind, placebo-controlled study.

<b>Study #</b>	<b>Trial Design</b>	<b>Dosage , route of administration and duration</b>	<b>Study patients (n)</b>	<b>Mean age (range) (yrs)</b>
Study 5 (ADAMO)	Phase 3, randomized, double-blind, placebo-controlled	PROLIA 60 mg or placebo SC injection every 6 months (Q6M) (2 doses)	242 men with osteoporosis (PROLIA: 121 Placebo: 121)	65 (31, 84)

The efficacy and safety of PROLIA in increasing bone mass in men with osteoporosis was demonstrated in a 1-year, randomized, double-blind, placebo-controlled, multinational study of men with low bone mass, who had a baseline BMD T-score between  $-2.0$  and  $-3.5$  at the lumbar spine or femoral neck. Men with a BMD T-score between  $-1.0$  and  $-3.5$  at the lumbar spine or femoral neck and with history of prior fragility fracture were also enrolled. Men with other diseases (such as rheumatoid arthritis, osteogenesis imperfecta, and Paget's disease) or on therapies that may affect bone were excluded from this study.

The 242 men enrolled in the study ranged in age from 31 to 84 years and were randomized to receive SC injections of either PROLIA 60 mg (n = 121) or placebo (n = 121) once every 6 months. Patients also received at least 1000 mg calcium and at least 800 IU vitamin D supplementation daily.

Previous fractures in the PROLIA and placebo groups were: 91 events in 47 patients (38.8%) vs. 76 events in 48 patients (39.7%) for any self-reported historical fractures since age 30, 18 events in 16 patients (13.2%) vs. 21 events in 20 patients (16.5%) for self-reported historical major osteoporotic fractures, and 43 events in 30 patients (24.8%) vs. 31 events in 25 patients (20.7%) for confirmed prevalent vertebral fractures, respectively.

The primary efficacy variable was percent change in lumbar spine BMD from baseline to 1 year. Secondary efficacy variables included percent change in total hip and femoral neck BMD from baseline to 1 year.

### **Effect on Bone Mineral Density (BMD)**

Treatment with PROLIA statistically significantly increased BMD at 1 year: the treatment differences in BMD at 1 year were: 4.8% (+5.7% PROLIA, +0.9% placebo,  $p < 0.0001$  [95% CI: 4.0%, 5.6%]) at the lumbar spine; 2.0% (+2.4% PROLIA, +0.3% placebo) at the total hip; and 2.2% (+2.1% PROLIA, 0.0% placebo) at femoral neck.

Consistent effects on BMD were observed at the lumbar spine regardless of baseline age, race, weight/body mass index (BMI), BMD, baseline testosterone levels and level of bone turnover.

The correlation between increased bone density and reduction of bone fracture in men with osteoporosis has not been established.

### **Bone Histology and Histomorphometry**

The transiliac crest bone biopsy substudy enrolled 29/242 patients at selected study centres in Study 5 (17 specimens in PROLIA group, 12 specimens in placebo group), after 12 months of treatment. Six (6) of the samples in the PROLIA group were adequate for full quantitative histomorphometry assessment. Qualitative histology assessments showed normal architecture and quality with no evidence of mineralization defects, woven bone, or marrow fibrosis in patients treated with PROLIA.

All subjects scheduled for the biopsy were to follow a double tetracycline/demeclocycline labelling procedure prior to undergoing the biopsy. The presence of double tetracycline labeling in a biopsy specimen provides an indication of active bone remodeling, while the absence of tetracycline label suggests suppressed bone formation. In patients treated with PROLIA, 6% (n = 1) had no tetracycline label present at the month 12 biopsy, while 100% of placebo-treated patients (n = 12) had double label present. When compared to placebo, treatment with PROLIA resulted in markedly reduced bone formation rates. However, the long-term consequences of this degree of suppression of bone remodeling are unknown.

### **Treatment to Increase Bone Mass in Men with Nonmetastatic Prostate Cancer receiving Androgen Deprivation Therapy (ADT), who are at high risk for fracture**

#### **Study Demographics and Design [Study 6]**

The efficacy and safety of PROLIA in the treatment of bone loss in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT) were demonstrated in a 3 year, randomized (1:1), double-blind, placebo-controlled, multinational study.

<b>Study #</b>	<b>Trial Design</b>	<b>Dosage , route of administration and duration</b>	<b>Study patients (n)</b>	<b>Mean age (range) (yrs)</b>
Study 6	Phase 3, randomized, double-blind, placebo-controlled	PROLIA 60 mg or placebo SC injection every 6 months for 3 years	1468 patients with nonmetastatic prostate cancer (PROLIA: 734 Placebo: 734)	75 (48, 97)

Men less than 70 years of age had either a BMD T-score at the lumbar spine, total hip, or femoral neck between -1.0 and -4.0, or a history of an osteoporotic fracture. The mean baseline lumbar spine BMD T-score was -0.4, and 22% of men had a vertebral fracture at baseline. The 1468 men enrolled ranged in age from 48 to 97 years (mean 75 years). Men were randomized to receive subcutaneous injections of either placebo (n = 734) or PROLIA 60 mg (n = 734) once every 6 months for a total of 6 doses. Randomization was stratified by age (< 70 years vs. ≥ 70 years) and duration of ADT at trial entry (≤ 6 months vs. > 6 months). All men regardless of age had histologically confirmed prostate cancer. Seventy-nine percent of patients received ADT for more than 6 months at study entry. All men were instructed to take at least 1000 mg calcium and 400 IU vitamin D supplementation daily.

### **Effect on Bone Mineral Density (BMD)**

The primary efficacy variable was percent change in lumbar spine BMD from baseline to month 24. Lumbar spine BMD was higher at 2 years in PROLIA-treated patients as compared to placebo-treated patients [-1.0% placebo, +5.6% PROLIA; treatment difference 6.7% (95% CI: 6.2, 7.1);  $p < 0.0001$ ].

With approximately 62% of patients followed for 3 years, treatment differences in BMD at 3 years were 7.9% (-1.2% placebo, +6.8% PROLIA) at the lumbar spine, 5.7% (-2.6% placebo, +3.2% PROLIA) at the total hip, and 4.9% (-1.8% placebo, +3.0% PROLIA) at the femoral neck ( $p < 0.0001$ ). Consistent effects on BMD were observed at the lumbar spine in relevant subgroups defined by baseline age, race, geographical region, weight/BMI, BMD, level of bone turnover, duration of ADT, and baseline history of vertebral fracture.

### **Effect on Vertebral Fractures**

An additional key secondary efficacy variable was the incidence of new vertebral fracture through month 36 diagnosed based on x-ray evaluation by two independent radiologists. The incidence of new vertebral fracture through month 12 and through month 24 were evaluated as exploratory endpoints. The subject-year adjusted incidence rate of new vertebral fractures at 3 years was 0.6 and 1.6 per 100 subject-years for PROLIA and placebo, respectively. PROLIA significantly reduced the incidence of new vertebral fractures at 3 years (adjusted  $p = 0.0125$ ). The relative risk reduction based on cumulative incidence of new vertebral fractures at 3 years was 62% (adjusted 95% Confidence Interval: 13, 83) (2.4% absolute risk reduction; adjusted 95% Confidence Interval: 0.4, 4.4). The relative risk reduction of new vertebral fractures was 85% (1.6% absolute risk reduction) at 1 year and 69% (2.2% absolute risk reduction) at 2 years.

### **Treatment to Increase Bone Mass in Women Receiving Adjuvant AI Therapy for Nonmetastatic Breast Cancer who have low bone mass and are at high risk for fracture**

#### **Study Demographics and Design [Study 7]**

The efficacy and safety of PROLIA in the treatment of bone loss in women receiving adjuvant aromatase inhibitor (AI) therapy for breast cancer was assessed in a 2 year, randomized (1:1), double-blind, placebo-controlled, multinational study.

<b>Study #</b>	<b>Trial Design</b>	<b>Dosage , route of administration and duration</b>	<b>Study patients (n)</b>	<b>Mean age (range) (yrs)</b>
Study 7	Phase 3, randomized, double-blind, placebo-controlled	PROLIA 60 mg or placebo SC injection every 6 months for 2 years	252 patients with nonmetastatic breast cancer (PROLIA: 127 Placebo: 125)	60 (35, 84)

Women had baseline BMD T-scores between -1.0 to -2.5 at the lumbar spine, total hip, or femoral neck, and had not experienced fracture after age 25. The mean baseline lumbar spine BMD T-score was -1.1, and 2.0% of women had a vertebral fracture at baseline. The 252 women enrolled ranged in age from 35 to 84 years (mean 60 years). Women were randomized to receive subcutaneous injections of either placebo (n = 125) or PROLIA 60 mg (n = 127) once every 6 months for a total of 4 doses. Randomization was stratified by duration of adjuvant AI therapy at trial entry ( $\leq 6$  months vs.  $> 6$  months). Sixty-two percent of patients received

adjuvant AI therapy for more than 6 months at study entry. All women were instructed to take 1000 mg calcium and at least 400 IU vitamin D supplementation daily.

### **Effect on Bone Mineral Density (BMD)**

The primary efficacy variable was percent change in lumbar spine BMD from baseline to month 12. Lumbar spine BMD was higher at 12 months in PROLIA-treated patients as compared to placebo-treated patients [-0.7% placebo, +4.8% PROLIA; treatment difference 5.5% (95% CI: 4.8, 6.3);  $p < 0.0001$ ].

With approximately 81% of patients followed for 2 years, treatment differences in BMD at 2 years were 7.6% (-1.4% placebo, +6.2% PROLIA) at the lumbar spine, 4.7 % (-1.0% placebo, +3.8% PROLIA) at the total hip, and 3.6% (-0.8% placebo, +2.8% PROLIA) at the femoral neck.

## **DETAILED PHARMACOLOGY**

### **Animal Pharmacology**

Denosumab is a fully human monoclonal antibody that binds to RANK ligand (RANKL) with high affinity and specificity. Denosumab blocks the interaction of RANKL with RANK, mimicking the endogenous effects of OPG. RANKL is a key mediator in the pathway required for the differentiation, survival, and activation of osteoclasts, the cells that resorb bone. Inhibition of the RANKL pathway by administration of denosumab leads to a rapid decrease in markers of bone resorption and numbers of osteoclasts.

The single- and multiple-dose pharmacokinetics of denosumab following intravenous or subcutaneous administration of denosumab were evaluated in mice, rats, and cynomolgus monkeys. Serum concentrations of denosumab were determined using a conventional sandwich enzyme-linked immunosorbent assay (ELISA) with a limit of quantification (LOQ) ranging from 0.78 to 5 ng/mL. In addition, tissue distribution (by liquid scintillation counting) and quantitative whole body autoradiography studies were conducted in cynomolgus monkeys following a single SC dose.

In mice and rats, species in which denosumab does not bind RANKL, the intravenous pharmacokinetics of denosumab were linear over the dose range of approximately 0.1 to 10 mg/kg, with low clearance and a volume of distribution at steady-state ( $V_{ss}$ ) that indicated a lack of extensive extravascular distribution. After a single SC dose (1 mg/kg), maximum serum denosumab concentrations ( $C_{max}$ ) occurred at 72 hours postdose in both species, and bioavailability was 86% in mice and 56% in rats.

Approximately 6- and 15-fold higher clearance was observed in huRANKL and knock-out mice lacking expression of the Fc neonatal receptor (FcRn), respectively, indicating important roles of RANKL and FcRn in denosumab disposition.

In cynomolgus monkeys, a species in which denosumab binds RANKL, the intravenous pharmacokinetics of denosumab were non-linear over the dose range of 0.0016 to 1 mg/kg (with approximately 16-fold higher clearance at the lowest relative to highest dose) but were approximately dose-linear between 1 and 3 mg/kg. At all doses, the  $V_{ss}$  indicated a lack of extensive extravascular distribution. The subcutaneous pharmacokinetics of denosumab were

also nonlinear in monkeys over the dose range of 0.0016 to 1 mg/kg, but were approximately dose-linear between 1 and 3 mg/kg.

## **Clinical Pharmacology**

### **Pharmacodynamics**

In clinical studies, treatment with 60 mg of PROLIA resulted in rapid reduction in the bone resorption marker serum type 1 C-telopeptide (CTX) within 6 hours of SC administration by approximately 70%, with reductions of approximately 85% occurring by 3 days. CTX levels were below the limit of assay quantitation (0.049 ng/mL) in 39 to 68% of subjects 1 to 3 months after dosing of PROLIA. CTX reductions were maintained over the 6-month dosing interval. At the end of each dosing interval, CTX reductions were partially attenuated from maximal reduction of  $\geq 87\%$  to  $\geq 45\%$  (range 45% to 80%), as serum denosumab levels diminished, reflecting the reversibility of the effects of PROLIA on bone remodelling. These effects were maintained with continued treatment. Consistent with the physiological coupling of bone formation and resorption in skeletal remodeling, subsequent reductions in bone formation markers were observed beginning 1 month after the first dose of PROLIA.

Bone turnover markers (bone resorption and formation markers) generally reached pre-treatment levels within 9 months after the last 60 mg SC dose. Upon re-initiation, the degree of inhibition of CTX by PROLIA was similar to that observed in patients initiating PROLIA treatment.

In a clinical study of postmenopausal women with low bone mass (N = 504) who were previously treated with alendronate for a median duration of 3 years, those transitioning to receive PROLIA experienced additional reductions in serum CTX, compared with women who remained on alendronate. In this study, the changes in serum calcium were similar between the 2 groups.

### **Pharmacokinetics**

Denosumab pharmacokinetics were not affected by the formation of binding antibodies to denosumab.

At the level of the administered dose, the pharmacokinetics of denosumab do not appear to be affected by gender, age (28 to 87 years), race, or disease state.

## **TOXICOLOGY**

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

#### **Carcinogenicity**

Since denosumab is highly species-specific and is not active in rodents, traditional rodent cancer bioassays could not be performed. RANKL inhibition (the target of denosumab) has been studied in a wide range of short-term animal models of cancer and shown no carcinogenic potential. Additionally, RANKL inhibition has shown no evidence of immunosuppression in a wide range of animal models.

## **Mutagenicity**

The genotoxic potential of denosumab has not been evaluated. Denosumab is a recombinant protein made up entirely of naturally-occurring amino acids and contains no inorganic or synthetic organic linkers or other non-protein portions. Therefore, it is unlikely that denosumab or any of its derived fragments would react with DNA or other chromosomal material.

## **Impairment of Fertility**

Denosumab had no effect on female fertility or male reproductive organs in monkeys at exposures that were 100- to 150-fold higher than the human exposure for 60 mg SC administered once every 6 months.

## **Animal Toxicology**

Denosumab is a potent inhibitor of osteoclastic bone resorption via inhibition of RANK ligand (RANKL).

In ovariectomized monkeys, once-monthly treatment with denosumab suppressed bone turnover and caused significant gain in BMD, and strength of cancellous and cortical bone. Bone tissue was normal with no evidence of mineralization defects, accumulation of osteoid, or woven bone.

Transition from 6-month alendronate treatment to denosumab in monkeys did not cause any meaningful decreases in serum calcium and significantly increased or maintained BMD of the whole body, lumbar spine, and distal radius. Bone strength parameters at these sites were maintained or improved with transition to denosumab, relative to continuous treatment with alendronate. Bone strength and reduction in bone resorption at all skeletal sites were maintained or improved in monkeys switched from alendronate to denosumab.

Since the biological activity of denosumab in animals is specific to non-human primates, evaluation of genetically engineered (“knockout”) mice or use of other biological inhibitors of the RANK/RANKL pathway, namely OPG-Fc, provided additional information on the pharmacodynamic properties of denosumab. RANK/RANKL knockout mice exhibited impairment of lymph node formation, had an absence of lactation due to inhibition of mammary gland maturation (lobulo-alveolar gland development during pregnancy), and exhibited reduced bone growth and lack of tooth eruption. Similar phenotypic changes were seen in a corroborative study in 2-week old rats given the RANK ligand inhibitor OPG-Fc. After 10 weeks on study, these changes were partially reversible in this model when dosing with the RANKL inhibitors was discontinued. Refer to Table 11 Summary of Preclinical Toxicity and Reproductive Studies with Denosumab for details of the individual study results.

**Table 11. Summary of Preclinical Toxicity and Reproductive Studies with Denosumab**

Type of Study	Species and strain	Number per sex per group	Route of Administration	Dose (mg/kg) and dosing regimen	Study Duration	Treatment related findings	NOAEL (mg/kg)
Repeated-dose Toxicity	Cynomolgus monkey	6	Subcutaneous (SC) or Intravenous (IV)	Once weekly: 0, 0.1, 1.0, & 10.0 (SC); 10.0 (IV)	1 month dosing with 3 months recovery	Consistent with the pharmacological action of denosumab, there were rapid and marked decreases in circulating markers of bone turnover at all doses. Correlating with these changes, there was increased bone mineral density in males dosed at 1 and 10 mg/kg. With the exception of bone mineral density which tended to be maintained, these changes were recovered or recovering following 3 treatment-free months.  There were no treatment related effects on organ weights or histopathology findings	10 (SC and IV)
	Cynomolgus monkey	8	Subcutaneous	Once monthly: 0, 1, 10, 50	6 and 12 months with 3 months recovery	Consistent with the pharmacological action of denosumab, there were rapid and marked decreases in circulating markers of bone turnover at 10 and 50 mg/kg. Correlating to these changes, there was increased bone mineral density, bone mineral content, cortical area and thickness, and bone strength parameters in males dosed at 50mg/kg, and females dosed at 10 and 50 mg/kg. In addition, there was enlargement of the growth plates, decreased osteoblasts and osteoclasts, and decreased chondroclasis at 10 and 50 mg/kg. These changes were recovered or recovering following 3 treatment-free months. There were no treatment related changes in ophthalmoscopy, cardiovascular physiology, sperm motility and morphology, circulating immunoglobulins and lymphocyte subsets, or organ weights.	50
Female Fertility	Cynomolgus monkey	6 Females	Subcutaneous	Once weekly: 0, 2.5, 5, 12.5	Over 2 menstrual cycles before mating and for 4 weeks after mating	No treatment related effects on cyclicity, circulating reproductive hormones, mating success.	12.5
Embryo-fetal	Cynomolgus	16	Subcutaneous	Once weekly:	Gestation days	No treatment related effects on mother or embryonic	12.5



Type of Study	Species and strain	Number per sex per group	Route of Administration	Dose (mg/kg) and dosing regimen	Study Duration	Treatment related findings	NOAEL (mg/kg)
Development	monkey	Females		0, 2.5, 5, 12.5	20-50	development were observed. Peripheral lymph nodes were not evaluated.	
Enhanced pre- and post-natal development	Cynomolgus monkey	29 Females	Subcutaneous	Once monthly: 0, 50	Gestation days 20 -22 to birth	<p>There were increased fetal losses during gestation, increased stillbirths and post-natal mortality (see Table 12.). Treatment-related findings in the offspring included decreased body weight gain and decreased neonatal growth; skeletal abnormalities resulting from impaired bone resorption during rapid growth, including bones at the base of the skull resulting in altered cranial shape and exophthalmos, reduced bone strength and treatment-related bone fractures; reduced hematopoiesis; decreased serum levels of bone resorption and bone formation biomarkers; tooth malalignment and dental dysplasia (in the absence of adverse effects on tooth eruption); infections; and absence of peripheral lymph nodes. Following a recovery period from birth out to 6 months of age, findings still observed were mildly reduced bone length (femoral, vertebral, jaw), reduced cortical thickness with associated reduced strength; extramedullary hematopoiesis; dental dysplasia; and the absence or decreased size of some lymph nodes. One infant had minimal to moderate mineralization in multiple tissues. The initially lower growth rates returned to, but never exceeded the growth rate in the control group, and hence, the infants exposed to denosumab remained smaller than control infants, as measured by body weight and morphometric measurements. For the denosumab-treated maternal animals, there was a decrease in serum levels of bone resorption and formation biomarkers, and serum alkaline phosphatase levels; recovery was evident by the end of the treatment-free period. Maternal mammary gland development was normal.</p> <p>At birth out to 1 month of age, infants had measurable blood levels of denosumab (22-621% of maternal levels). Only one infant had measurable concentrations of denosumab on BD91, and no infants had measurable concentrations on BD180. Generally, the effects</p>	A NOAEL was not identified

Type of Study	Species and strain	Number per sex per group	Route of Administration	Dose (mg/kg) and dosing regimen	Study Duration	Treatment related findings	NOAEL (mg/kg)
						observed in mothers and infants were consistent with the pharmacological action of denosumab.	
Safety Pharmacology	Cynomolgus monkey	3 Males	Subcutaneous	Single dose: 0, 0.3, 3, 30	7 days	No treatment related effects on heart rate, blood pressure, electrical activity of the heart, or respiratory rate were observed.	30
	Sprague Dawley weanling rats	71 male and 67 female	Subcutaneous	Rat OPG-Fc: 1, 10 mg/kg/week Murine RANK-Fc: 10 mg/kg/week	6 weeks	Increased bone volume, density and strength. Increased cancellous bone with reduced osteoclast number. Reduced long bone growth with altered growth plate morphology and increased thickness. Impaired tooth eruption and tooth root formation.	N/A
	Sprague Dawley neonatal rats	51 male and 49 female	Subcutaneous	Rat OPG-Fc or ALN: 5 µL/g/week for 6 weeks followed by 10 week treatment-free period	16 weeks	Ten weeks after the discontinuation of a 6-week course of OPG-Fc administration, neonatal rats exhibited evidence of restored bone resorption and partial normalization of bone density, size, and strength. Molar eruption, which had been substantially delayed during the administration of OPG-Fc, exhibited partial recovery in some animals within 10 weeks of its discontinuation. The relative increases in bone volume, density, and strength that occurred during 6 weeks of ALN administration were generally preserved 10 weeks after its discontinuation, whereas molar eruption did not recover within this timeframe. Modest epiphyseal growth plate changes persisted 10 weeks after discontinuing high-dose OPG-Fc. Bone size, body weight, and molar root development remained significantly reduced 10 weeks after discontinuation of OPG-Fc or ALN when compared to the vehicle control group.	N/A
Other Studies – Tissue Cross-reactivity	Cynomolgus monkey, rat, rabbit	N/A	<i>In Vitro</i>	5 or 25 µg/mL	N/A	Staining of lymphoid tissue in rabbit and cynomolgus monkey and staining of chondrocytes in rat were observed.	N/A

Type of Study	Species and strain	Number per sex per group	Route of Administration	Dose (mg/kg) and dosing regimen	Study Duration	Treatment related findings	NOAEL (mg/kg)
	Cynomolgus monkey, human	N/A	<i>In Vitro</i>	1 or 10 µg/mL	N/A	Staining of lymphoid tissue in monkey, but no staining in human tissue was observed.	N/A
	Human	N/A	<i>In Vitro</i>	1 or 10 µg/mL	N/A	Staining of lymphoid tissue was observed.	N/A

N/A = not applicable

**Table 12. Total Fetal Losses<sup>c</sup>, all Groups**

Dose, (mg/kg)	Total No. Pregnant Females; Infants Born (M/F)	Gestation Day (GD) of Fetal Loss	% Fetal Loss by Dose Level			
			Full Gestation	First Trimester (GD20 to GD50)	Third Trimester Total (≥GD100)	Third Trimester Stillbirths (≥GD140)
0	29; 22 (13/9)	GDs 32, 32, 33, 104, 152, 157, 170	24.1% (7/29)	10.3% (3/29)	13.8% (4/29)	10.3% (3/29)
50	29; 16 (7/9)	GDs 31, 32, 33, 33, 46, 88 <sup>a</sup> , 132, 151, 156 <sup>a</sup> , 157, 158, 160, 168	40.7% (11/27) 44.8%** (13/29)	17.2% (5/29)	22.2% (6/27) 24.1%** (7/29)	18.5% (5/27) 20.7%** (6/29)
Historical Control Data <sup>b</sup>			24.8% (33/133)	6.8% (9/133)	15.8% (21/133)	9.0% (12/133)
Range			(6.7 to 38.9%)	(0 to 11.8%)	(0 to 28.6%)	(0 to 16.7%)

<sup>a</sup> Two adult females were excluded from fetal loss calculations except for first trimester because each had an anti-drug anti-body (ADA) response beginning at GD76 with subsequent decrease in pharmacologic effect (bone biomarkers) prior to fetal loss; results indicated by a double asterisk (\*\*) include these ADA-positive adult females.

<sup>b</sup> Based on 8 enhanced PPND studies conducted at the Testing Facility from 2008 to 2010.

<sup>c</sup> Fetal losses occurring prior to GD140 were considered abortions; those occurring on or after GD140 were considered stillbirths.

## REFERENCES

1. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. *J Clin Endocrinol Metab.* 2008;93:2149-2157.
2. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 Trial. *J Bone Miner Res.* 2009;24:153-161.
3. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med.* 2009;361:756-765.
4. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. *Proc Natl Acad Sci.* 1999;96:3540-3545.
5. Ellis GK, Bone HG, Chlebowski R, et al. Randomized Trial of Denosumab in Patients Receiving Aromatase Inhibitors for Nonmetastatic Breast Cancer. *J Clin Onc.* 2008;26(30):4875-4882.
6. Kendler DL, Roux C, Benhamou CL, et al. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning from Alendronate Therapy. *J Bone Miner Res.* 2010;25(1):72-81.
7. Kendler DL, Bessette L, Hill CD, et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. *Osteoporos Int.* 2010;21:837-846.
8. Kostenuik PJ, Warmington K, Grisanti M, et al. RANKL inhibition with AMG 162, a fully human MAb, causes sustained suppression of bone resorption and increased BMD in knockin mice expressing humanized RANKL. *J Bone Min Research.* 2005;20(suppl 1):S259.
9. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell.* 1998;93:165-176.
10. Orwoll ES, Teglbjaerg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. *J Clin Endocrinol Metab.* 2012;97(9):3161-3169.
11. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ* 2010; 182: 1870.
12. Papapoulos S, Lippuner K, Roux C, et al. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension. Poster: Abstract LB-MO26. Poster presented at: American Society for Bone and Mineral Research 2013 Annual Meeting; October 4-7, 2013; Baltimore, MD, USA.
13. Reid IR, Miller PD, Brown JP, et al. Effects of Denosumab on bone histomorphometry: The FREEDOM and STAND studies. *J Bone Miner Res.* 2010;25(10):2256-2265.
14. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: Differing effects of Denosumab and Alendronate. *J Bone Miner Res.* 2010;25(8):1886-1894.

15. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med.* 2009;361:745-755.

## PART III: CONSUMER INFORMATION

**PrProlia®**  
(denosumab)

*pronounced PRO-lee-ah*

This leaflet is part III of a three-part "Product Monograph" published when PROLIA (denosumab) was authorized for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about PROLIA. Contact your doctor or pharmacist if you have any questions about the drug.

**Please read this information carefully before you start to take your medicine, even if you have just refilled your prescription. Some of the information may have changed. Keep this pamphlet since you may need to refer to it after starting treatment with PROLIA.**

**Remember that your physician has prescribed this medicine only for you. Never give it to anyone else.**

### ABOUT THIS MEDICATION

#### What the medication is used for:

PROLIA is used to:

- treat osteoporosis (thinning and weakening of the bone) in women after menopause who
  - have an increased risk for fractures or;
  - cannot use other osteoporosis medicines, or other osteoporosis medicines did not work well.
- increase bone mass in men with osteoporosis at high risk for fracture.
- increase bone mass and may reduce fractures that occur when medication to reduce testosterone levels are taken for the treatment of prostate cancer that has not spread to other parts of the body (nonmetastatic).
- increase bone mass in women who are receiving certain treatments for breast cancer, which has not spread to other parts of the body (nonmetastatic) and at high risk of fracture.

#### What is osteoporosis?

Bone is constantly changing. There are special cells in the body called osteoclasts whose primary function is to remove bone. There is another type of cell called osteoblasts, which are bone-forming cells. In normal bone, there is a balance between the actions of these two cells. In people with osteoporosis, this balance no longer exists. Instead, the cells that remove bone work overtime, removing bone faster than new bone can be created. The result is bone that is thinner, weaker and more likely to break. Osteoporosis may occur without any pain or other symptoms. Sometimes the first symptom of osteoporosis is a fragility fracture, a broken bone that may be caused by a minor fall, or simple activities such as lifting groceries or getting out of bed. A fragility fracture can significantly increase the risk

of future fractures. Aside from prescribing PROLIA, your doctor can guide you in other ways to manage your bone health.

Surgery or medicines that stop the production of estrogen or testosterone used to treat patients with breast or prostate cancer can also lead to bone loss. This may cause some bones to become weaker and break more easily.

#### What it does:

PROLIA works differently than other osteoporosis medications. It is a RANK ligand inhibitor. RANK ligand is a protein which activates the cells that break down bone (osteoclasts). PROLIA blocks RANK ligand to stop the cells that break down bone. This action strengthens your bones by increasing bone mass and lowers the chance of breaking bones of the hip, spine, and nonspinal sites.

#### When PROLIA should not be used:

You should not use PROLIA if you:

- Are allergic to denosumab or any other ingredient of PROLIA. Allergic reactions (eg, rash, hives, or in rare cases, swelling of the face, lips, tongue, throat, or trouble breathing) have been reported.
- Have low calcium levels in your blood (hypocalcemia)
- Are less than 18 years of age (see also **What the medication is used for** above and **WARNINGS AND PRECAUTIONS** below)
- Are pregnant or breast-feeding
- Are a woman before menopause [unless you have been diagnosed with breast cancer (see also **What the medication is used for** above and **WARNINGS AND PRECAUTIONS** below)]
- Are currently taking denosumab, under the brand name XGEVA.
- Do not have access to a health professional or trained injector

#### What the medicinal ingredient is:

The medicinal ingredient in PROLIA is denosumab.

#### What the important nonmedicinal ingredients are:

The other ingredients are sorbitol, acetate, polysorbate 20, water for injection and sodium hydroxide. The needle cover on the single use prefilled syringe contains dry natural rubber (latex), which should not be handled by persons allergic to this substance.

#### What dosage forms it comes in:

PROLIA is a liquid for injection, available in a prefilled syringe.

PROLIA is a clear, colourless to slightly yellow solution. Do not use if the solution is cloudy.

**WARNINGS AND PRECAUTIONS****What important information do I need to know about taking PROLIA?**

PROLIA contains the same medicine as another drug called XGEVA, but at a different dose. If you are being treated with PROLIA, you should not be taking XGEVA or vice versa.

There is an increased risk of skin infection (cellulitis) with PROLIA therapy, most commonly on the leg. See a doctor urgently if you develop swollen, red, hot or painful skin, with or without fever.

You should take calcium and vitamin D supplements as recommended by your healthcare professional.

BEFORE you use PROLIA talk to your doctor or pharmacist if you:

- Have low blood calcium
- Cannot take daily calcium and vitamin D
- Had parathyroid or thyroid surgery (glands located in your neck)
- Have been told you have trouble absorbing minerals in your stomach or intestines (malabsorption syndrome)
- Have kidney problems or are on kidney dialysis
- Have ever had an allergic reaction to PROLIA
- Plan to have dental surgery or teeth removed
- Have a history of cancer
- Could become pregnant
- Are allergic to rubber or latex

Tell your doctor and pharmacist about all the medicines you take, including prescription and nonprescription drugs, vitamins, and herbal supplements, and keep an up-to-date list of all of them.

The needle cover on the single use prefilled syringe contains dry natural rubber (latex), which should not be handled by persons allergic to it.

PROLIA may interfere with normal bone and tooth development in fetuses, nursing babies, and children under 18 years of age. Children under 18 years of age should not take PROLIA.

Women who are pregnant or could become pregnant should not take PROLIA. If you become pregnant while taking PROLIA, stop taking PROLIA and tell your doctor right away.

Nursing mothers should not take PROLIA. It may also interfere with breastfeeding.

PROLIA may lower levels of calcium in the blood. Low blood calcium should be treated before receiving PROLIA. Symptoms of low blood calcium may include muscle spasms, twitches, cramps, numbness or tingling in hands, feet or around the mouth, and weakness. Some patients may not have any symptoms of low calcium. Tell your doctor if you have any of these symptoms.

Tell your doctor right away if you have symptoms of infection, including:

- Fever or chills
- Skin that looks red, swollen, hot or tender to touch
- Severe abdominal pain
- Frequent or urgent need to urinate or burning feeling when you urinate

Tell your doctor if you have any of the following symptoms of skin problems that do not go away or get worse:

- Redness
- Itching
- Rash
- Dry or leathery skin
- Open, crusted or peeling skin
- Blisters

After you start PROLIA:

- Take good care of your teeth and gums, and see your dentist regularly
- If you have a history of dental problems (such as poorly fitting dentures or gum disease), see your dentist before starting PROLIA
- Tell your dentist that you are taking PROLIA, especially if you are having dental work

A dental condition called osteonecrosis of the jaw (ONJ) which can cause tooth and jawbone loss has been reported in patients treated with PROLIA. The risk of ONJ may increase with length of time on PROLIA. Tell your doctor and dentist immediately about any dental symptoms, including pain or unusual feeling in your teeth or gums, or any dental infections.

Some people have developed unusual fractures in their thigh bone. Contact your doctor if you experience new or unusual pain in your hip, groin, or thigh.

After your treatment with PROLIA is stopped, it is possible that broken bones in your spine may occur especially if you have a history of broken bones in the spine. Do not stop taking PROLIA without first talking with your doctor. If your PROLIA treatment is stopped, discuss other available treatment options with your doctor.

**INTERACTIONS WITH THIS MEDICATION**

In a drug interaction study, PROLIA (60 mg) did not interfere with the action of a drug called midazolam which is metabolized (broken down) by a certain liver enzyme called cytochrome P450 3A4. No drug interactions are expected with PROLIA and other drugs metabolized by this enzyme in women with postmenopausal osteoporosis.

You should discuss with your doctor any medications or vitamins or herbal products you are taking before using PROLIA.



**PROPER USE OF THIS MEDICATION**

PROLIA is administered as a single injection under the skin (subcutaneous) every 6 months. The injection can be in your upper arm, upper thigh, or abdomen. It can be given any time by a health professional or by a trained injector, with or without food.

Your prefilled syringe may be left outside the refrigerator to reach room temperature (up to 25°C) before injection. This will make the injection more comfortable. See instructions for injection.

Keep all medicines, including PROLIA, away from children.

Do not share a PROLIA product with others, even if they have a similar disease.

**Usual dose:**

The usual dose of PROLIA is 60 mg administered once every 6 months. You should also take supplements of calcium and vitamin D.

**Missed dose:**

If you miss a dose you should receive your next dose as soon as convenient. Schedule your next dose 6 months from the date of your last injection.


**Overdose:**

In case of drug overdose, contact a health professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

**INSTRUCTIONS FOR INJECTION:**

**IMPORTANT:** In order to minimize accidental needle sticks, the PROLIA single use prefilled syringe has a green safety guard that should be manually activated after the injection is given.

**DO NOT** slide the green safety guard forward over the needle before administering the injection – it will lock in place and prevent injection.




The green safety guard should be activated (slide over the needle) **AFTER** the injection.

The grey needle cap on the single use prefilled syringe contains dry natural rubber (a derivative of latex), which should not be handled by persons sensitive to latex.


**Step 1 – Remove Grey Needle Cap**

Remove Needle Cap



**Step 2 – Administer Injection**

Insert needle and inject all the liquid



**DO NOT** put grey needle cap back on needle.


**Step 3 – Immediately Slide Green Safety Guard over Needle**

**With the needle pointing away from you**


Hold the prefilled syringe by the clear plastic finger grip with one hand. Then, with the other hand, grasp the green safety guard by its base and gently slide it towards the needle until the green safety guard locks securely in place and/or you hear a ‘click.’

**DO NOT** grip the green safety guard too firmly – it will move easily if you hold and slide it gently.

Hold clear Finger Grip



Gently slide green safety guard over needle and lock securely in place. Do not grip green safety guard too firmly when sliding over needle.



Immediately dispose of the syringe and needle cap in the nearest sharps container. DO NOT put the needle cap back on the used syringe.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

Like all medicines, PROLIA can cause side effects, although not everybody gets them.

Possible side effects include:

- Pain, sometimes severe, in the muscles, joints, arms, legs or back.
- Low blood calcium (hypocalcemia).
- Symptoms of low blood calcium may include muscle spasms, twitches, cramps, numbness or tingling in fingers, toes or around the mouth.
- Allergic reactions (eg, rash, hives, or in rare cases, swelling of the face, lips, tongue, throat, or trouble breathing).
- Skin condition with itching, redness and/or dryness (eczema). Injection site reactions were uncommon.
- Skin infection with swollen, red area of skin, that feels hot and tender and may be accompanied by fever (cellulitis).
- Common cold (runny nose or sore throat)
- Broken bones in the spine after stopping PROLIA (multiple vertebral fractures)

These are not all the possible symptoms or side effects you may experience; if you are concerned about any effects you experience you should contact your doctor.

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

Symptom / effect	Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist	
	Only if severe	In all cases		
Common (≥ 1%, in 1 to 10% of patients)	√			
Uncommon (≥ 0.1%, < 1%)		√		
Rare (≥ 0.01%, < 0.1%)		√	√	√

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

Symptom / effect		Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
		Only if severe	In all cases	
Very Rare (< 0.01%)	Unusual thigh bone fractures		√	

**HOW TO STORE IT**

Keep out of the reach and sight of children.

When prescribed PROLIA, you will likely need to fill your prescription at a pharmacy. Store PROLIA in your refrigerator at 2°C to 8°C until your injection appointment with your health professional or trained injector. Do not freeze.

When removed from the refrigerator, PROLIA must be kept at room temperature (up to 25°C) in the original carton and must be used within 30 days.

Store in original carton in order to protect from light.

Do not use PROLIA after the expiry date which is printed on the carton and label. The expiry date refers to the last day of that month.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer required.

**REPORTING SUSPECTED SIDE EFFECTS**

**You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:**

- Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to:
    - Canada Vigilance Program
    - Health Canada
    - Postal Locator 0701D
    - Ottawa, Ontario
    - K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect® Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

**NOTE:** *Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.*

**MORE INFORMATION**

For more information or to obtain the full product monograph, prepared for health professionals, contact the ProVital Support Program information line, toll-free at: 1-877-776-1002 or visit [www.prolia.ca](http://www.prolia.ca).

This leaflet was prepared by Amgen Canada Inc.

Last revised: August 24, 2017